Summary Table of Study Protocol

Title	Incidence of Cardiovascular and Cerebrovascular Events Among Postmenopausal Women and Men With Osteoporosis Who Initiated Treatment With Denosumab or Zoledronic Acid -- A Retrospective Cohort Study
Protocol version identifier	*Study Number 20190038 V1*
Date of last version of the protocol	*September 25, 2019*
EU Post Authorization Study (PAS) Register No	*N/A*
Active Substance	Denosumab
Medicinal Product	Prolia®
Product Reference	EMEA/H/C/001120
Procedure Number	N/A
Joint PASS	Yes
Research Question and Objectives	Among postmenopausal women and men with osteoporosis who initiated treatment with denosumab or zoledronic acid: a) Describe the prevalence of cardiovascular risk factors at initiation of treatment b) Describe the incidence rates for outcomes of: (i) myocardial infarction (MI) (ii) stroke (iii) a composite endpoint of MI and stroke (iv) a composite endpoint of MI, stroke, and all-cause mortality c) Assess comparability between subjects treated with denosumab and subjects treated with zoledronic acid, after inverse probability of treatment weighting adjustment for confounding, using standardized mean differences d) If the assessment indicates sufficient post-adjustment comparability, compare the risk of outcomes between subjects treated with denosumab and subjects treated with zoledronic acid
Country of Study	United States

Author	PPD VMD, PhD PPD PhD, MPH PPD PhD, MPH PPD PhD PPD MD, PhD PPD MD PPD PhD, ScD

Marketing Authorization Holder

Marketing authorization holder	Amgen Ltd on behalf of Amgen Europe B.V. 240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD
MAH Contact	PPD Senior Manager, Regulatory Affairs Amgen PPD

Study Design Schema



- [1] 455 day baseline period where subjects are continuously enrolled: assess no prior use of index therapy and cardiovascular risk factors
- [2] The index date is the date of the first prescription for each drug type meeting eligibility criteria between 01 October 2010 and 31 December 2017
- [3] Study subjects will be followed from initiation of denosumab or zoledronic acid (index date) through to the first occurrence of any of the following: outcome of interest, end of study medication, start of different OP medication, diagnosis of Paget's disease or cancer (excluding non-melanoma skin cancer), treatment with chemotherapy, hormonal therapy, or radiation therapy for cancer, disenrollment, 3 years after index date, or end of available data in the database. In the Optum CDM, where data on death are available, follow-up will also end at patient death.
- Subgroup analyses will be performed in the following populations:
  1) no chronic renal disease, 2) stage I and stage II chronic kidney disease,
  3) stage III chronic kidney disease, 4) stage IV chronic kidney disease,
  5) stage V chronic kidney disease, and 6) end stage renal disease

1. Table of Contents

List of Tables

List of Appendices

2. List of Abbreviations

Average treatment effect (ATE)	ATE
Current Procedural Terminology	CPT
Clinformatics® Data Mart	CDM
Commercial Claims and Encounters	CCE
Confidence Interval	CI
Chronic Kidney Disease	CKD
Denosumab	DMAB
Diagnosis Related Group	DRG
European Economic Area	EEA
European Union	EU
Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial	FREEDOM trial
Hazard Ratio	HR
Health Insurance Portability and Accountability	HIPAA
Healthcare Common Procedure Coding System	HCPCS
Health Care Financing Agency	HCFA
HORIZON Pivotal Fracture Trial	HORIZON-PFT
The International Classification of Diseases, Ninth Revision, Clinical Modification	ICD-9-CM
The International Classification of Diseases, Tenth Revision, Clinical Modification	ICD-10-CM
Inverse probability of censoring weighting	IPCW
Inverse probability of treatment weighting	IPTW
International Birth Date	IBD
Interquartile range	IQR
Incidence Rate Ratio	IRR
Lightweight Directory Access Protocol	LDAP
Male Osteoporosis	MOP
Myocardial infarction	MI
National Drug Code	NDC
Osteoprotegerin	OPG
Osteoporosis	OP
Personal Health Identifier	PHI
Postmenopausal Osteoporosis	PMO
Present on Admission	POA
Pharmacovigilance Risk Assessment Committee	PRAC
Receptor Activator of Nuclear factor-Kappa B Ligand	RANKL
Risk Mitigation Plan	RMP
Standardized Mean Difference	SMD
Standard Operating Procedure	SOP
Social Security Administration	SSA
Zoledronic Acid	ZA

3. Responsible Parties

PPD VMD PhD, Amgen Inc.

PPD PhD, MPH, Amgen Inc.

PPD PhD, MPH, Amgen Inc.

PPD PhD, Amgen Inc.

PPD MD, Amgen Inc.

PPD PhD, ScD, Amgen Inc.

4. Abstract

- **Study Title**

  Incidence of Cardiovascular and Cerebrovascular Events Among Postmenopausal Women and Men with Osteoporosis Who Initiated Treatment with Denosumab or Zoledronic Acid -- A Retrospective Cohort Study

- **Study Background and Rationale**

  The Pharmacovigilance Risk Assessment Committee (PRAC) requested Amgen to study the potential increased risk of cardiovascular and cerebrovascular events in a real-world Prolia target population with a sufficiently long follow-up and number of events, while taking into account any confounding by indication. The overall approach of the proposed study, including study design, US data sources, endpoints, comparator group, and overall analytic approach was previously agreed upon with the agency.

- **Research Question and Objectives**

  Among postmenopausal women and men with osteoporosis who initiated treatment with denosumab or zoledronic acid:

  a) Describe the prevalence of cardiovascular risk factors at initiation of treatment

  b) Describe the incidence rates for outcomes of:

  (i) myocardial infarction (MI)

  (ii) stroke

  (iii) a composite endpoint of MI and stroke

  (iv) a composite endpoint of MI, stroke, and all-cause mortality

c) Assess comparability between subjects treated with denosumab and subjects treated with zoledronic acid, after inverse probability of treatment weighting adjustment for confounding, using standardized mean differences

d) If the assessment indicates sufficient post-adjustment comparability, compare the risk of outcomes between subjects treated with denosumab and subjects treated with zoledronic acid

- **Study Design**

  Retrospective cohort study

- **Study Population/Data Source**

  The study population includes postmenopausal women and men with osteoporosis who initiated treatment with denosumab or zoledronic acid in the United States.

  Analyses will be carried out in two separate administrative claims databases:

  1) IBM Watson Health (formerly Truven) *MarketScan*® Truven MarketScan Commercial and Medicare Supplemental and Coordination of Benefits Databases [MarketScan® CCE], and
  2) Optum Clinformatics® Data Mart [CDM])

- **Summary of Subject Eligibility Criteria**

  For inclusion criteria, subjects included in the study must meet the following criteria:

  - Receipt of denosumab or zoledronic acid between 01 October 2010 and 31 December 2017. The index date is defined as the first date of administration.
  - Subjects must be either women or men aged 55 years or older at index date
  - At least 455 days of continuous enrollment in the data source preceding index date; as zoledronic acid is given yearly, a 455 day (ie, 15 month) look-back period will enable assessment of past use (Choi et al, 2017).

  For exclusion criteria, subjects are excluded from the study for any of the following criteria assessed during the 455 days preceding the index date:

  - Subjects with possible use of study medications (denosumab or zoledronic acid) for indications other than for osteoporosis, including diagnoses of Paget's disease of bone or cancer (excluding non-melanoma skin cancer).
  - History of recent stroke or MI events.
  - Previous administrations of study medications (denosumab or zoledronic acid) prior to the index date. Look-back will include all available data (with a minimum required look-back period of 455 days prior to index date).

- **Follow-up**

  Study subjects will be followed from initiation of denosumab or zoledronic acid (index date) through to the first occurrence of any of the following: outcome of interest, end

of study medication, start of different OP medication, diagnosis of Paget's disease or cancer (excluding non-melanoma skin cancer), treatment with chemotherapy, hormonal therapy, or radiation therapy for cancer, disenrollment, 3 years after index date, or end of available data in the database. In Optum CDM, where data on death are available, follow-up will also end at patient death.

- **Variables**

  Outcome Variables

  Cardiovascular end points will be defined using algorithms that have been previously validated in US administrative claims databases.

  - Myocardial infarction will be identified with a hospital discharge diagnosis code of acute MI.
  - Stroke will be defined with a hospital discharge diagnosis code of ischemic or hemorrhagic stroke.
  - In addition, a composite outcome including hospitalized MI or hospitalized stroke will be assessed.
  - A composite outcome including hospitalized MI, hospitalized stroke, and all-cause mortality will be assessed in the Optum database, where information on all-cause death is available.

  Exposure Variable(s)

  1. Denosumab: the dosing interval for denosumab 60 mg (Prolia) is once every six months (182 days). Subjects will be considered continuously exposed to denosumab from the date of first administration through the end of an allowable gap period of 60 days following the standard dosing interval (182-day) after the last-recorded denosumab administration.
  2. Zoledronic acid: The dosing interval for zoledronic acid is once a year (365 days). Subjects will be considered continuously exposed to zoledronic acid from the date of first administration through the end of an allowable gap period of 60 days following the standard dosing interval (365-days) after the last-recorded zoledronic acid administration.

Other Covariate(s)

Subject demographic and clinical characteristics, measured during the baseline period, will be evaluated for descriptive purposes and creation of propensity scores. These covariates will relate to the following factors:

- Demographic characteristics (e.g., age, sex, region, cohort entry year, race (the Optum database contains information on race))
- Comorbidities, including risk factors for cardiovascular/cerebrovascular outcomes and osteoporosis (e.g., hypertension, hyperlipidemia, heart failure, atrial fibrillation, transient ischemic attack, peripheral vascular disease, obesity, type 2 diabetes, chronic kidney disease, osteoporosis diagnosis and medications, osteoporosis-related fracture)
- Cardiovascular procedures (e.g., coronary artery bypass graft and percutaneous coronary intervention)
- Medication history (e.g., lipid-lowering agents, antihypertensive drugs, anticoagulants, and antiarrhythmics)
- Patient health-seeking behavior (e.g., number of physician office outpatient visits, emergency room visits, hospitalizations, receipt of flu vaccination)

- **Study Size**

Simple counts in the data sources to support protocol development suggest that the study will include approximately 50,000 subjects newly exposed to denosumab and about 30,000 to zoledronic acid in the MarketScan® CCE database, and approximately half the number of subjects in each corresponding treatment cohort in Optum CDM. Power calculations were based on the following assumptions: (1) a fixed sample size of 40,000 subjects in Optum CDM and 80,000 subjects in MarketScan® CCE; (2) an allocation ratio (denosumab: zoledronic acid) of 5:3; (3) maximum follow-up period of 36 months; (4) annual rate of loss-to-follow-up of 50% in both treatment cohorts; (5) one-sided alpha of 0.025; (6) constant hazard rate of outcomes over time. Based on these assumptions, we expect to have ≥ 80% power to detect up to a 1.8-fold increased risk (HR = 1.8) in MarketScan® CCE (up to 2-fold increased risk, HR = 2.0, in Optum CDM) of outcomes in subjects initiating denosumab relative to those initiating zoledronic acid, for outcomes with annualized incidence rates as low as 0.1%.

- **Data Analysis**

Subject demographic and clinical characteristics will be summarized by cohort of exposure. Discrete variables will be summarized using frequencies and proportions, and continuous variables will be summarized using means and standard deviation (SD) or medians and interquartile range (IQR), as appropriate. Incidence rates (number of

events divided by person-time of follow-up) of the various outcomes in each exposure cohort will be estimated along with 95% confidence intervals as a measure of precision. Propensity scores will be calculated for each subject using multivariable logistic regression modeling based on subject baseline demographic and clinical characteristics. If sufficient comparability (based on quantitative assessment of balance in propensity scores) can be achieved between the two treatment groups, the risk of the outcomes will be compared between the two treatment groups via inverse probability of treatment weight (IPTW) and inverse probability of censoring weight (IPCW) methods. Inverse probability of treatment weights will be created using the propensity scores to minimize confounding in the comparison of subjects initiating denosumab versus subjects initiating zoledronic acid. Application of IPTW will result in an estimation of the population average treatment effect (ATE), and IPCW will minimize bias resulting from informative censoring. Cox proportional hazards regression will be used to compare the risk of subjects experiencing the outcome among subjects initiating denosumab relative to that in subjects initiating zoledronic acid. This analysis will be further detailed by estimating risk differences and plotting risk differences with 95% confidence interval bands.

5. Amendments and Updates

Amendment or Update Number	Date	Section of Study Protocol	Amendment or Update	Reason
N/A				

6. Milestones

Milestone	Planned date
Start of data collection	*TBD (Pending EMA protocol approval)*
End of data collection	*TBD*
Milestone	**Planned date**
Registration in the EU PAS register	*TBD*
Final report of study results	*TBD*

7. Rationale and Background

7.1 Diseases and Therapeutic Area

Denosumab is a fully human IgG2 monoclonal antibody that binds to RANK ligand (RANKL) and blocks the interaction of RANKL with RANK. Denosumab (Prolia) was first approved on 26 May 2010 [the international birth date (IBD)] for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures at the approved dose of 60 mg in the European Union (EU)/European Economic Area (EEA). The indications have been extended to include indications for treatment of osteoporosis in men (2014) and bone loss associated with long-term systemic glucocorticoid therapy (2018). Nonclinical and clinical studies conducted to date demonstrate that denosumab is well tolerated and exhibits a favorable safety profile.

Elevated levels of osteoprotegerin (OPG) have been associated with coronary artery disease in cross-sectional studies but this association has been contradicted by preclinical and epidemiological studies demonstrating that the lack of OPG or unopposed RANKL is associated with cardiac calcification. Due to these conflicting results and because denosumab inhibits RANKL, a theoretical concern for denosumab to affect progression of atherosclerosis exists. (EU RMP 25).

Zoledronic acid is a nitrogen-containing bisphosphonate with high affinity for mineralized bone. Zoledronic acid inhibits osteoclast-mediated bone resorption, largely through inhibition of osteoclast farnesyl pyrophosphate synthase. In the EU, zoledronic acid (Aclasta, Novartis) given as a 5 mg single dose intravenously every 12 months is indicated for the treatment of osteoporosis in postmenopausal women and adult men at increased risk of fracture, osteoporosis associated with long-term systemic glucocorticoid therapy in postmenopausal women and adult men at increased risk of fracture, and for the treatment of Paget's disease of the bone in adults. Aclasta received marketing authorization in the EU on 15 Apr 2005.

In selecting zoledronic acid as an appropriate active comparator for denosumab, we considered the propensity for denosumab subjects to have greater risk factors for cardiovascular outcomes (ie, potential confounding factors such as older age, greater history of fractures and other comorbidities) than subjects treated with oral bisphosphonates (Yusuf et al, 2016; Amgen data on file). Women with postmenopausal osteoporosis (PMO) treated with zoledronic acid tend to be similar in age and other

clinical characteristics compared to PMO subjects treated with denosumab (Yusuf et al, 2016; Amgen data on file). In addition, the annual dosing interval of zoledronic acid more closely resembles the biannual dosing interval of Prolia and persistence with therapy is more comparable between the two therapies (Durden et al, 2017).

7.2 Rationale

In the pivotal 3-year placebo-controlled FREEDOM trial, in which postmenopausal women with osteoporosis were randomized to either denosumab 60 mg q6 months or placebo, deaths and serious adverse events possibly related to cardiovascular disease were adjudicated by an independent expert panel and were of similar incidence between treatment groups. (Cummings, S. R., et al. 2009)

More recently, however, small numerical imbalances in investigator-reported adverse cerebrovascular events were observed in the 12-month primary analysis of study 20101217 in subjects with glucocorticoid induced osteoporosis; small numerical imbalances in investigator-reported adverse cardiovascular and cerebrovascular events were reported in a pooled analysis of studies in which subjects transitioned from bisphosphonate therapy to Prolia therapy. (PRAC Assessment Report PSUR Procedure# EMEA/H/C/PSUSA/00000954/201709)

EU PRAC requested Amgen to study the potential increased risk of cardiovascular and cerebrovascular events in a real-world Prolia target population with a sufficiently long follow-up and number of events, while taking into account any confounding by indication. The risk of cardiovascular disease with denosumab treatment in a real-world clinical setting has been previously assessed in a cohort study using administrative claims data from a large commercial US health plan. When compared with zoledronic acid, after 1:1 propensity score matching, denosumab was not associated with an increased risk of MI (IRR 1.24 (95% CI 0.25 to 6.14)) or stroke (IRR 0.31 (95% CI 0.03-2.77)) (Choi et al, 2017). This study included 2,467 subjects in each treatment group, and a total of 6 MI events and 5 stroke events were observed across treatment groups over a 1-year period.

Amgen proposes to conduct a more comprehensive study assessing MI and stroke over a 3-year period, in two different real-world data systems covering more than 70,000 denosumab-treated subjects through 2017.

Key aspects of the study were agreed upon with the agency in 2018 including study design, US data sources, endpoints, comparator group, and overall analytic approach. (PRAC Assessment Report PSUR Procedure# EMEA/H/C/PSUSA/00000954/201709)

7.3 Statistical Inference (Estimation or Hypothesis[es])

This study includes a descriptive analysis of the baseline prevalence of cardiovascular risk factors and incidence rates of the following outcomes of interest among postmenopausal women and men with osteoporosis initiating treatment with denosumab or zoledronic acid: MI, stroke, a composite outcome including MI and stroke, and a composite outcome including MI, stroke, and all-cause mortality (analysis of this last outcome is restricted to the Optum database that contains information on death). If subjects in the two treatment groups are sufficiently comparable, based on quantitative assessment of balance in propensity scores between groups, the outcomes will be compared between treatment groups under the hypothesis that there exists no difference in rates of outcomes between subjects initiating treatment with denosumab versus those initiating treatment with zoledronic acid.

8. Research Question and Objectives

Among postmenopausal women and men with osteoporosis, evaluate the risk of cerebrovascular and cardiovascular events in subjects initiating treatment with denosumab relative to those initiating treatment with zoledronic acid.

8.1 Primary

The objectives of this study are as follows:

Among postmenopausal women and men with osteoporosis who initiated treatment with denosumab or zoledronic acid:

a) Describe the prevalence of cardiovascular risk factors at initiation of treatment
b) Describe the incidence rates, up to 36 months, for outcomes of:
   (i) myocardial infarction (MI)
   (ii) stroke
   (iii) a composite endpoint of MI and stroke
   (iv) a composite endpoint of MI, stroke, and all-cause mortality (this analysis will only be assessed in the Optum database where information on all-cause death is available

c) Assess comparability between subjects treated with denosumab and subjects treated with zoledronic acid, after inverse probability of treatment weighting adjustment for confounding, using standardized mean differences

d) If the assessment indicates sufficient post-adjustment comparability, compare the risk of outcomes between subjects treated with denosumab and subjects treated with zoledronic acid

9. Research Methods

9.1 Study Design

This is a retrospective cohort study employing a new user design, using secondary data and conducting analyses separately in two large US administrative claims data systems.

9.2 Setting and Study Population

9.2.1 Study Period

Subjects will be identified for inclusion into the study population between 01 October 2010 (initial date of use for specific coding for denosumab within data source) through and 31 December 2017 (end date of available data). Data availability will extend to July 2009 to accommodate the identification of baseline variables.

9.2.2 Subject Eligibility

9.2.2.1 Inclusion Criteria

Subjects will be included in the study population if they meet the following criteria:

- Receipt of one or more administrations (ie, claim containing national drug code (NDC) or Healthcare Common Procedure Coding System (HCPCS) code) for denosumab or zoledronic acid between 01 October 2010 and 31 December 2017.
  - The index date is defined as the first date of administration of study medication (ie, denosumab or zoledronic acid) observable in the data between 01 October 2010 and 31 December 2017.
- Subjects must be women or men age 55 years or older at index date.
- At least 455 days of continuous enrollment preceding index date. A 455-day enrollment is included because the dosing interval for zoledronic acid is once a year (365 days). Assessing 455 days (ie, 15 months) of look-back period will permit identification of past use.

9.2.2.2 Exclusion Criteria

Subjects will be excluded from the study if they meet any of the following criteria during the 455 days preceding the index date (ie, the baseline period).

- Subjects with any of the following will be excluded to assure that denosumab is given for the osteoporosis indication (Hoffman, V., et al. 2014)
  - Diagnosis of Paget's disease of bone (Appendix C)
  - Diagnosis of cancer (excluding non-melanoma skin cancer) (Appendix C)

  - Treatment with chemotherapy,
  - Treatment with hormonal therapy for cancer,
  - Treatment with radiation or radiation therapy for cancer

- To identify incident events, subjects with a history of stroke or MI events during the 455-day baseline period will be excluded.
- Previous administration for denosumab or zoledronic acid prior to the index date. Look-back will include all available data (with a minimum required look-back period of 455 days prior to index date). (Kent, S. T., et al. 2015).
  - For this exclusion, denosumab use prior to 01 October 2010 will be identified by nonspecific codes (CPT codes: J3490and J3590) in combination with ICD-9 diagnostic codes for osteoporosis prior to 01 October 2010.

9.2.3 Matching

Not Applicable

9.2.4 Baseline Period

The baseline period will be defined as 455 days before the index date (excluding the index date).

9.2.5 Study Follow-up

Study subjects will be followed from initiation of denosumab or zoledronic acid (index date) through to the first occurrence of any of the following: outcome of interest, end of study medication, start of different OP medication, diagnosis of Paget's disease or cancer (excluding non-melanoma skin cancer), treatment with chemotherapy, hormonal therapy for cancer, or radiation therapy for cancer, disenrollment, 3 years after index date, or end of available data in the database. In the Optum CDM, where data on death are available, follow-up will also end at patient death.

9.3 Variables

9.3.1 Exposure Assessment

1. Denosumab: the dosing interval for denosumab 60 mg (Prolia®) is once every six months (182 days). Subjects will be considered continuously exposed to denosumab from the date of first administration through the end of an allowable gap period of 60 days following the standard dosing interval (182 days) after the last recorded denosumab administration.

Denosumab will be identified using HCPCS codes (C9272 - Injection, denosumab, 1 mg, effective 01 October 2010 to 31 December 2011; J0897 - Injection, denosumab, 1 mg, effective 01 Jan 2012); and National Drug Codes (NDC) (55513071001- strength 60 mg).

2. Zoledronic acid: The osteoporosis dosing interval for zoledronic acid is 5 mg once a year (365 days). Subjects will be considered continuously exposed to zoledronic acid from the date of first administration through the end of an allowable gap period of 60 days following the standard dosing interval (365 days) after the last-recorded zoledronic acid administration.

Zoledronic acid will be identified using current HCPCS codes (J3488 Injection, zoledronic acid (Reclast) 1 mg effective from 01/01/2008, J3489- Injection, zoledronic acid, 1 mg effective from 01/01/2014, Q2051- Injection, zoledronic acid, not otherwise specified, 1 mg effective from 07/01/2013, Q4095-Injection, zoledronic acid (Reclast), 1 mg effective from 07/01/2007) and current NDC codes (eg, 00078043561, 23155018631, 25021083082, 35356035101, 42023016301,43598033111, 55111068852 – strength 5 mg).

The procedure codes specific for denosumab (C9272 & J0897) and the later codes for zoledronic acid (Q2051 & J3488) are not specific to osteoporosis (Prolia/Reclast) versus cancer (XGEVA/Zometa) treatment. The use of these codes is acceptable, because we are excluding subjects with cancer at baseline and censoring during follow-up.

9.3.2 Outcome Assessment

Cardiovascular end points will be similarly defined using validated algorithms that have also been used in previous studies of MI and stroke (Kim et al, 2017).

- Myocardial infarction will be identified with a hospital discharge diagnosis code of acute MI (ICD-9 codes: 410.x0, 410.x1; ICD-10 codes: I21., I21.0, I21.0x, I21.1, I21.1x, I21.2, I21.2x, I21.3, I21.4, I21.9).
- Stroke will be defined with a hospital discharge diagnosis code of ischemic or hemorrhagic stroke (ICD-9 codes: 430, 431, 433.x1, 434.x1, 436; ICD-10 codes: I60.xx, I61.xx, I63.0xx-I63.6xx, I63.8, I63.9).
- Composite endpoint of MI and stroke
- Composite endpoint of MI, stroke, and all-cause mortality. Analysis of this outcome is restricted to the Optum database that contains information on death.

9.3.3 Covariate Assessment

Covariates selected have been identified to be risk factors for cerebrovascular/cardiovascular outcomes and/or osteoporosis and will be used for the description for subjects starting each therapy and for propensity score analysis. They will be identified using algorithms that utilize inpatient and outpatient ICD-9-CM/ICD-10-CM diagnoses codes, CPT or HCPCS procedure codes, or NDC codes for prescription therapies.

- Demographic characteristics (eg, age, sex, region, cohort entry year, race (in Optum database which contains information on race))
- Comorbidities, including risk factors for cardiovascular/cerebrovascular outcomes and osteoporosis (eg, hypertension, hyperlipidemia, heart failure, atrial fibrillation, transient ischemic attack, peripheral vascular disease, obesity, type 2 diabetes, chronic kidney disease, osteoporosis diagnosis and medications, osteoporosis-related fracture)
- Cardiovascular procedures (eg, coronary artery bypass graft and percutaneous coronary intervention)
- Medication history (eg, lipid-lowering agents, antihypertensive drugs, anticoagulants, and antiarrhythmics)
- Patient health-seeking behavior (eg, number of physician office outpatient visits, emergency room visits, hospitalizations, receipt of flu vaccination)

9.3.4 Validity and Reliability

Study endpoints of MI and stroke definitions will be identified using algorithms that have been validated and found to have a positive predictive value of greater than 85% in Medicare (Kiyota et al, 2004; Andrade et al, 2012; Kumamaru et al, 2014) and commercial claims (Cutrona et al, 2013).

9.4 Data Sources

As previously described in earlier correspondences with PRAC, (EMA/PRAC/222725/2018) analyses will be conducted separately in two US databases, which were selected based on criteria of having validated endpoints for hospitalized MI and stroke, having sufficient number of endpoints among denosumab subjects, and providing timely results.

IBM Watson Health (formerly Truven) MarketScan Commercial and Medicare Supplemental and Coordination of Benefits Databases (MarketScan® CCE)

The Commercial database contains the healthcare experience for corporate employees and their dependents within a variety of fee-for-service and managed care plans in the United States; Medicare Supplemental and Coordination of Benefits database contains the healthcare experience for United States retirees with Medicare supplemental insurance. Both the Medicare-covered portion of payment (represented as Coordination of Benefits Amount) and the employer-paid portion are included in this database.

The MarketScan® CCE data link paid claims and medical encounter data to detailed subject information across sites in the US. The database contains individual-level data on enrollment, medical encounters, and inpatient and outpatient medical claims and prescription drug claims on approximately 17 million employees and their dependents,

annually, covered under a variety of fee-for-service and capitated health plans, including exclusive provider organizations, preferred provider organizations (PPOs), point of service plans, indemnity plans, and health maintenance organizations (HMOs). Enrollees maintain their unique identifier even if they change health plans as long as they continue to work for the same employer. The CCE databases contain diagnoses coded through the International Classification of Diseases, 9th version (ICD-9-CM) prior to October 2015 and 10th version (ICD-10-CM), surgical procedures using Current Procedural Terminology (CPT) codes, and pharmacy data including prescriptions identified through NDC and HCPCS codes, the date the prescription was filled, and the quantity dispensed. Undiagnosed conditions, and lifestyle and biometric factors (eg, smoking status) are not well captured in the data. The data are HIPAA compliant and all data are anonymized.

Optum Clinformatics® Data Mart (CDM)

Optum Clinformatics® Data Mart (CDM) is a medical claims database which represents the medical experience of insured employees and their dependents from affiliated commercial and Medicare Advantage plans. Subjects must have both medical and pharmacy coverage to be included in the database. The underlying insured population from which the data are drawn spans across all 50 US states and is racially/ethnically diverse. The database contains fully adjudicated eligibility, pharmacy, procedure, and medical claims data for subjects enrolled in a large US health plan (UnitedHealth Group). The health plan provides coverage for physician, hospital, and prescription drug services, and captures medical claims or encounter data from all available health care sites (inpatient hospital, outpatient hospital, emergency room, physician's office, surgery center, etc.) for virtually all types of provided services. Each facility inpatient admission record contains information on diagnoses (recorded using ICD-9-CM and ICD-10-CM diagnosis codes), procedures (recorded with ICD-9-CM and ICD-10-CM procedure, CPT, or HCPCS codes), and Present on Admission (POA) codes. Data are linked at the subject level by a unique identifier that is consistent across services, health plans, and time, so subjects can be tracked over multiple years even if they switch health plans. Laboratory test results can be linked to medical and pharmacy claims data for a limited subpopulation of enrollees within the CDM. Undiagnosed conditions, and lifestyle and biometric factors (eg, smoking status) are not well captured in the data.

The date of death is captured from a number of different sources, but, if the same member is identified as deceased in two or more sources, the following priority is used to

identify the month and year of death: (1) discharge status of death from confinement record, (2) diagnosis / diagnosis related group (DRG) code for death, and (3) Social Security Administration (SSA) Death Master File. Linkage to the Death Master File is made in a deterministic way, using personal health information (PHI), including social security number and at least one other identifying information, available to the health insurer. The SSA currently captures death data from several sources, including, but not limited to, funeral homes and families of the deceased.

9.5 Study Size

The required study size is dependent on the number of subjects initiating treatment with denosumab and zoledronic acid in the data sources, the expected annual loss to follow-up, and the expected incidence rate of the outcomes of interest in the study population. Simple counts in the data sources to support protocol development suggest that the study will include approximately 50,000 subjects initiating treatment with denosumab and 30,000 initiating treatment with zoledronic acid in the MarketScan® CCE database, and approximately one-half the number of subjects in each corresponding treatment cohort in the Optum CDM. Anticipated loss to follow-up is informed by the rate of disenrollment as well as subject persistence with therapy as subjects will be censored at end of study medication. The median period of enrollment in these databases is approximately 18 months. A previous study in the MarketScan® CCE database indicated that among women with PMO initiating treatment with denosumab, approximately 70% remain persistent on therapy at the end of 12 months (Durden et al, 2017). Expectations for the annual incidence of MI and stroke in this study population are informed by a previous study within the Optum database (Choi et al, 2017). In this study, which included men and postmenopausal women with osteoporosis initiating treatment with denosumab or zoledronic acid, the incidence rates of hospitalized MI and hospitalized stroke outcomes were approximately 1 to 2 per 1,000 person-years.

Table 1 and Table 2 show the power available to detect an increased risk of outcome among subjects initiating denosumab relative to those initiating zoledronic acid, given the number of subjects available in the study databases. Power calculations were based on the following assumptions: fixed sample size of 40,000 subjects in Optum CDM and 80,000 subjects in MarketScan® CCE, allocation ratio (denosumab: zoledronic acid) 5:3, maximum follow-up period of 36 months, annual rate of loss-to-follow-up of 50% in both treatment cohorts, one-sided alpha of 0.025, and constant hazard rate of outcomes over time. Based on these assumptions, we expect to have ≥ 80% power to detect up to a

1.8-fold increased risk (HR = 1.8) in MarketScan® CCE (up to 2-fold increased risk, HR = 2.0, in Optum CDM) of outcomes in subjects initiating denosumab relative to those initiating zoledronic acid, for outcomes with annualized incidence rates as low as 0.1%.

Table 1. Power Calculation Over a Range of Annualized Rates of Outcome for Optum CDM

Hazard ratio (DMAB vs ZOL)	Annualized rate of outcome	1.3	1.5	1.6	1.8	2.0	2.2	2.5
Power for Total N = 40,000 (Simulation)	Annualized rate of outcome							
	0.8%	0.77	0.99	1	1	1	1	1
	0.5%	0.57	0.93	0.98	1	1	1	1
	0.3%	0.37	0.76	0.88	0.98	1	1	1
	0.2%	0.26	0.57	0.72	0.91	0.98	1	1
	0.1%	0.15	0.32	0.41	0.63	0.79	0.91	0.98
	0.05%	0.08	0.17	0.23	0.35	0.49	0.63	0.78

Table 2. Power Calculation Over a Range of Annualized Rates of Outcome in MarketScan® CCE

Hazard ratio (DMAB vs ZOL)	Annualized rate of outcome	1.3	1.5	1.6	1.8	2.0	2.2	2.5
Power for Total N = 80,000 (Simulation)	Annualized rate of outcome							
	0.8%	0.97	1	1	1	1	1	1
	0.5%	0.86	1	1	1	1	1	1
	0.3%	0.65	0.96	1	1	1	1	1
	0.2%	0.48	0.86	0.95	1	1	1	1
	0.1%	0.26	0.58	0.71	0.91	0.98	1	1
	0.05%	0.15	0.32	0.41	0.63	0.79	0.91	0.98

9.6 Data Management

After the receipt of the commercially available claims databases from Optum CDM and MarketScan® CCE, the data are checked for errors and completeness and loaded into a production Hadoop-based environment for analysis. The data are secured using industry-standard technology via LDAP security groups and accessed only by authorized

personnel using an analytic workbench which includes tools such as SAS, Databricks, R and Impala. Statistical programmers only have read access to the source data. All data management and statistical programming procedures are governed by standard operating procedures (SOPs), and users are only authorized to access the systems and data when they have completed and certified on required training (including SOPs).

9.6.1 Obtaining Data Files

Data are received from Optum CDM and MarketScan® CCE via download using Amazon WorkSpace (AWS) S3 buckets. Data may be encrypted with a password sent separately. A manifest detailing contents (list of tables, fields, and number of rows) is also included in the transfer to enable Amgen to verify that the transfer completed successfully.

9.6.2 Review and Verification of Data Quality

The MarketScan® CCE databases are constructed through collection and standardization of raw data from the appropriate payers and linking files across time and data type to create a comprehensive and efficient set of database tables. Variables specific to particular employers are added, as are details on clinical information such as therapeutic class, generic product identifier, therapeutic group, etc. Other enhancements are made to improve data quality and efficiency, for example: updating diagnosis and procedure codes to reflect changes in codes over time if necessary; creating a common synthetic subject identifier that enables subjects to be tracked over time and across data types; integrating benefit plan characteristics, enrollment, outpatient pharmaceutical claims, and medical/surgical data. A comprehensive series of edits on the reasonableness and validity of the data are conducted. For example, checking diagnosis against age and gender, charge against payment, zip codes, diagnosis and procedure codes against lists of valid values, etc. Data are collected when close to 100% of claims have been paid, which results in a lag time between date of service and date of payment of about 3-6 months. No data editing, beyond what is applied in the database production process, will be conducted for this study.

The Optum CDM is a de-identified, Health Insurance Portability and Accountability (HIPAA) compliant, closed system of claims, which undergo audits and quality control procedures by the insurer at regular intervals. The coding of medical claims conforms to insurance industry standards, including the use of designated claims forms (eg, physicians use the Health Care Financing Agency [HCFA]-1500 format and hospitals use the UB-92 format).

Data received from Optum CDM and MarketScan® CCE are checked against the vendor-provided manifest to verify that every table, field and row they sent was received by Amgen. Amgen runs additional data quality checks: The Achilles Heel report from OHDSI for OMOP data, and custom data checks comparing prior refreshes to the current data.

9.7 Data Analysis

9.7.1 Planned Analyses

9.7.2 Planned Method of Analysis

9.7.2.1 General Considerations

To describe the prevalence of cardiovascular risk factors at initiation of treatment, by denosumab therapy and by zoledronic acid therapy, discrete variables will be summarized using frequencies and proportions, and continuous variables will be summarized using means and standard deviation (SD) or medians and interquartile range (IQR), as appropriate.

To describe the incidence rates for outcomes, by denosumab therapy and by zoledronic acid therapy, the number of events will be divided by person-time of follow-up. Incidence rates will be accompanied by the corresponding 95% confidence intervals as a measure of precision.

To compare the risk of outcomes between subjects treated with denosumab and subjects treated with zoledronic acid, the baseline characteristics will be used to create propensity scores. If sufficient comparability (based on quantitative assessment of balance in propensity scores) can be achieved between the two exposure groups, IPTW and IPCW methods will be used to compare the risk of the outcomes between the two groups. Inverse probability of treatment weights will be created using the propensity scores to minimize confounding in the comparison of subjects initiating treatment with denosumab versus subjects initiating treatment with zoledronic acid. Application of IPTW will result in an estimation of the population average treatment effect (ATE), and IPCW will minimize bias resulting from informative censoring. The use of IPTW and IPCW aims to address the potential confounding due to initial treatment assignment as well as any potentially-informative censoring by loss to follow-up.

9.7.2.2 Missing or Incomplete Data and Lost to Follow-up

There will be no imputation of missing data in this study. Descriptive analyses (number and percentage) will be used to describe the extent of loss to follow-up in each exposure

group. Reasons for lost to follow-up (e.g., end of study medication, disenrollment, end of data availability in database, etc.) will also be described in each cohort.

9.7.2.3 Descriptive Analysis

9.7.2.3.1 Description of Study Enrollment

The selection of the study population from the MarketScan® CCE and Optum CDM databases, according to the study eligibility criteria, will be summarized in tabular format, and will include frequencies and proportions of subjects remaining at each step of subject selection.

9.7.2.3.2 Description of Subject/Patient Characteristics

Demographic and clinical characteristics (see Section 9.3.3 Covariate Assessment) will be summarized for each data system overall and by treatment groups. Categorical variables will be presented as number and proportion/ percent of subjects and continuous variables presented as mean with standard deviation and/or median with interquartile range, as appropriate.

9.7.2.4 Analysis of the Primary Endpoints

Study endpoints include:

- Myocardial infarction
- Stroke (ischemic or hemorrhagic)
- Composite outcome of MI or stroke
- Composite outcome including MI, stroke, or all-cause mortality in the Optum CDM

For each outcome in each data system, the incidence of each endpoint will be estimated using two methods. To address objective 2, simple incidence rates ([total number of subjects with at least one event in the cohort / sum of followed person time to the first censoring event in the cohort] X 100), will be estimated for each outcome of interest in each cohort. These incidence rates will not account for treatment selection or informative censoring. For objective 3, cumulative risk will be estimated in each treatment group using inverse-probability of treatment and censoring weighted estimation functions. The approach addresses confounding in initial treatment assignment and potentially-informative censoring by loss to follow-up (Hubbard et al, 2000; Robins & Finkelstein, 2000). Propensity scores will be estimated for each subject in the cohort using multivariable logistic regression including appropriate baseline covariates related to subject demographic and clinical characteristics outlined in Section 9.3.3. The propensity score is a balancing score (Rosenbaum and Rubin, 1983): conditional on the

propensity score, the distribution of observed baseline covariates will be similar between treatment groups. Appropriate variables for inclusion in a propensity score are either true confounders (because inclusion of these covariates reduces bias) or are variables that are related to the outcome (because these variables increase precision). Inclusion of variables related only to the exposure but weakly related to the outcome should be avoided because these variables only slightly reduce bias, but may substantially decrease precision (Brookhart et al, 2006). A similar method will be used to construct the censoring weights. Predictors of censoring may include demographic characteristics, medication usage, disease history, and utilization of medical resources. Differences in baseline subject characteristics between the treatment cohorts will be assessed in the initial (unweighted) study population and the inverse probability of treatment weighted population using the standardized mean difference (SMD). A SMD greater than 0.1 (10%) will represent residual imbalance for any covariate. The overlap of the propensity score distribution will also be visualized to assess possible positivity violations. A previous study in the Optum CDM database indicates that we have reasonable likelihood of achieving balance between our treatment groups. (Choi et al, 2017)

If these assessments indicate balance in baseline covariates between treatment cohorts, adjusted hazard ratios (with 95% confidence intervals) will be estimated, using Cox proportional hazards regression, to compare the risk of outcome among subjects initiating treatment with denosumab relative to that in subjects initiating treatment with zoledronic acid. This analysis will be further detailed by estimating risk differences (patient year adjusted) and plot risk differences with 95% confidence interval bands.

9.7.2.5 Sensitivity Analysis

9.7.2.5.1 Subgroup Analysis

Denosumab, unlike zoledronic acid, is not contraindicated in subjects with creatinine clearance less than 35 mL/min or in those with evidence of acute renal impairment. Therefore, we expect that subjects treated with denosumab will have a higher prevalence of renal impairment than subjects treated with zoledronic acid. Because renal insufficiency may be a strong indicator for cardiovascular risk, we expect that our crude association would be biased away from the null with denosumab treated subjects at an increased baseline risk of the outcomes. To address this potential bias, we will perform subgroup analyses in the following populations 1) no chronic renal disease, 2) stage I and stage II chronic kidney disease, 3) stage III chronic kidney disease,

4) stage IV chronic kidney disease, 5) stage V chronic kidney disease, and 6) end stage renal disease.

9.7.2.5.2 Stratified Analysis

N/A

9.7.2.5.3 Sensitivity Analysis for Residual Confounding and Bias

We will apply quantitative bias analyses to assess the extent of unmeasured confounding that would be required to refute an observed difference in outcome incidence between cohorts. The rule-out method has been described previously (Schneeweiss S, 2006), is publicly available (Division of Pharmacoepidemiology and Pharmacoeconomics [DoPE], 2019) and has been applied extensively in the literature (Weintraub WS et al, 2012). An alternative method of evaluating unmeasured confounding involves assessing the strength of the measured confounders by removing each confounder individually from the model to develop a distribution of the point estimate of the hazard ratios to display the strength of the measured confounding. Assuming the unmeasured confounders fall within this distribution, the distribution can be used to inform the potential magnitude and direction of the unmeasured confounders on the validity of the effect estimate. One or more of these methods will be explored, as appropriate.

Death may be a competing risk in these analyses. To address this potential bias, we will perform a competing risk analysis in Optum for the outcomes of MI, stroke, and the composite MI/stroke outcome using an appropriate competing risk model (Fine and Gray 1999, Kalbfleish and Prentice 2011). Additionally, we will evaluate a composite outcome of MI/stroke/death in Optum. We will not perform these analyses in MarketScan since very few subjects have death data; only those who died in the hospital have this recorded. However, comparing the primary results from Optum (not accounting for death as a competing risk) to the sensitivity results (accounting for competing risk) will provide insight into the extent of potential bias caused by competing risks.

Due to differing pathophysiology and preponderance of ischemic versus hemorrhagic stroke we will further characterize the incidence of stroke by performing a sensitivity analysis restricting stroke events to ischemic stroke events. (Benjamin et al, 2017; Sacco et al, 2013)

9.7.3 Analysis of Safety Endpoint(s)/Outcome(s)

This study is designed to assess the potential risk of cerebrovascular and cardiovascular outcomes among subjects exposed to denosumab for treatment of osteoporosis. All study analyses are relevant to assessment of this potential risk.

9.8 Quality Control

Statistical analyses in the final analytical datasets will be conducted by two persons and cross-checked for quality assurance.

The data vendors (external to Amgen) are responsible for data quality and integrity during data collection, and each data vendor has their own rigorous process of verifying the accuracy of their data.

Statistical programming and analysis are governed by Standard Operating Procedures (SOPs) that dictate the level of quality control required for each study. In the case of a safety study, independent programming (a second programmer producing the same results independently) will be used. All files (programs, logs, output, analytic datasets, code lists) will be stored in a secure Amgen file server, and at the conclusion of the study will be made read-only.

9.9 Limitations of the Research Methods

9.9.1 Internal Validity of Study Design

9.9.1.1 Measurement Error(s)/Misclassification(s)

Presence of a diagnosis code on a medical claim is not positive presence of disease, as the diagnosis may be incorrectly coded or included as a rule-out criterion rather than indicating actual disease. We expect this bias to be non-differential with respect to cardiovascular risk and thus for the resulting effect estimate to be biased toward the null.

We include a 15-month baseline period to exclude prevalent use of study medication. The median period of enrollment in these databases is approximately 18 months. This could potentially reduce our length of follow-up and non-differential under capture of events could reduce the precision of our estimates. However, the current study has a significant increase in sample size over the previous study conducted in the Optum database (Choi et al, 2017). In addition, we account for the 18-month median enrollment in our power calculations by estimating the annual rate of loss-to-follow-up at 50%.

9.9.1.2 Selection Bias

Selection bias may be a concern if there is significant loss to follow-up. We will compare median enrollment times post-index date to examine any differences between the two treatment groups.

9.9.1.3 Confounding

To address confounding, we are estimating the cumulative risk of each outcome using inverse-probability of treatment and censoring weighted estimation functions. We also plan to conduct subgroup analyses within groups categorized by stage of chronic renal disease. However, residual confounding is always a potential risk. We will use quantitative bias analysis to assess the potential for residual confounding from unmeasured confounders.

9.9.2 External Validity of Study Design

The study population is limited to individuals with commercial health coverage or private Medicare supplemental coverage. As such, its findings may not be generalizable to other populations, such as populations of uninsured women or older women who receive healthcare coverage through other plans such as government plans (eg, Medicare).

9.9.3 Analysis Limitations

For the comparator analysis, the use of zoledronic acid as a comparator may bias the results towards indicating an increased relative risk of cerebrovascular/cardiovascular events associated with denosumab. Although there are mixed conclusions in the literature on the potential positive effects of bisphosphonates on lipid metabolism, vascular calcification, and atherosclerosis (Pennanen et al, 1995; Ylitalo et al, 1994), there is a lack of strong evidence from randomized clinical trials to suggest effects on clinical cardiovascular outcomes (Kim et al, 2015; Kranenburg et al, 2016). In the HORIZON-PFT trial, in which 7,765 women were randomized to receive either zoledronic acid or placebo, the incidence of most cardiovascular events was similar between the 2 study groups, including stroke (2.3% in both arms over a 3-year period) and MI (1% in treated group versus 1.2% in placebo group over a 3-year period) (Black et al, 2007). On the other hand, a recent 6-year randomized, placebo-controlled, double-blind trial of 2000 women with osteopenia (Reid, IR 2018) provided evidence to suggest a cardioprotective effect of zoledronate with odds ratios and 95% confidence intervals MI 0.61 (0.36–1.02); coronary-artery revascularization 0.72 (0.41–1.27); stroke 0.85 (0.44–1.63); and composite of vascular events (sudden death, MI, coronary-artery revascularization, or stroke) of 0.72 (0.41–1.27). However, there was no evidence of

effect on atrial fibrillation OR (95% C.I.) 0.98 (0.67–1.44), transient ischemic attack 1.66 (0.85–3.24) or sudden death 3.01 (0.3–28.9).

9.9.4 Limitations Due to Missing Data and/or Incomplete Data

The variables in this study, including osteoporosis therapy (based on prescription claims or lack thereof), and presence of comorbidities, procedures, and concomitant medications, will be measured by searching for diagnosis, procedure, and drug codes. Thus, the data will be captured to the extent that the database is appropriately populated with these codes. We expect the missingness to be nondifferential and to have limited impact on the study.

10. Protection of Human Subjects

10.1 Institutional Review Board/Independent Ethics Committee (IRB/IEC)

This is a retrospective cohort study using the IBM Watson Health (formerly Truven) *MarketScan® Commercial Claims and Encounters* Database and Optum CLINFORMATICS Database and is considered secondary data collection. No primary data collection will occur, consent is not needed, and Institutional Review Board approval is not needed.

11. Collection, Recording, and Reporting of Safety Information and Product Complaints

This study is analyzing secondary data from medical claims including the IBM Watson Health (formerly Truven) *MarketScan® Commercial Claims and Encounters* Database and Optum CLINFORMATICS Database. The safety outcomes that are listed in section Outcome Assessment 9.3.2 will be analyzed in this study. These will be reported in aggregate in the final study report as cumulative incidence rates. See section Outcome Assessment 9.3.2 for safety outcomes and definitions. Submission of safety outcomes as individual safety reports to Amgen is not required. Safety events suspected to be related to any medicinal product should be reported to the local authority in line with the local country requirements.

12. Administrative and Legal Obligations

12.1 Protocol Amendments and Study Termination

Not applicable

13. Plans for Disseminating and Communicating Study Results

This study will not be submitted for publication but will be submitted to the EMA and registered on European Network of Centres for Pharmacoepidemiology and Pharmacovigilance site.

14. References

Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. *Pharmacoepidemiol Drug Saf.* 2012;21 Suppl 1:100–128.

Benjamin EJ, Blaha MJ,Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. 2017 Circulation 135(10): e146-e603.

Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med*. 2007;356:1809-1822.

Brookhart, M.A., et al., Variable selection for propensity score models. Am J Epidemiol, 2006. 163(12): p. 1149-56.

Choi N-K, Solomon DH, Tsacogianis TN, Landon JE, Son HJ, Kim SC. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. *J Bone Miner Res*. 2017;32(3):611-617.

Cummings, S. R., et al. (2009). "Denosumab for prevention of fractures in postmenopausal women with osteoporosis." N Engl J Med **361**(8): 756-765.

Cutrona, S. L., et al. (2013). "Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program." Pharmacoepidemiol Drug Saf 22(1): 40-54.

Division of Pharmacoepidemiology and Pharmacoeconomics. Department of Medicine Brigham and Women's Hospital Harvard Medical School. Web site. http://www.drugepi.org. Accessed 04032019

Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. *Arch Osteoporos.* 2017;12(1):22.

Fine J and Gray R. A proportional hazards model for the subdistribution of a competing risk. J American Statistical Association 1999;94:496-509.

Hoffman, V., et al. (2014). "Development and evaluation of an algorithm to identify users of Prolia(®) during the early postmarketing period using health insurance claims data.

Hubbard A, Laan M van der, Robins JM. Nonparametric locally efficient estimation of the treatment specific survival distribution with right censored data and covariates in observational studies. In: Halloran M, Berry D, editors. Statistical models in epidemiology, the environment, and clinical trials. New York, NY: Springer; 2000.

Kent, S. T., et al. (2015). "Optimal use of available claims to identify a Medicare population free of coronary heart disease." Am J Epidemiol **182**(9): 808-819.

Kalbfleish, JD, Prentice, RL. The Statistical Analysis of Failure Time Data: Second Edition. John Wiley & Sons. 2011

Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. *PLoS One.* 2015;10(4): e0122646.

Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. *Arthritis Rheumatol.* 2017;69(6):1154-1164.

Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. *Am Heart J.* 2004;148(1):99–104.

Kranenburg G, Bartstra JW, Weijmans M, et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. *Atherosclerosis.* 2016;252:106-115.

Kumamaru H, Judd SE, Curtis JR, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims. *Circ Cardiovasc Qual Outcomes.* 2014;7(4):611–619.

Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. *Pharm Res.* 1995;12(6):916-922.

Reid IR, Horne AM, Mihov B. "Fracture Prevention with Zoledronate in Older Women with Osteopenia." N Engl J Med 2018 379(25): 2407-2416.

Robins, J. M. and D. M. Finkelstein (2000). "Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests." Biometrics 56(3): 779-788.

Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.

Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2013 Stroke 44(7): 2064-2089.

Schneeweiss, S. (2006). "Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics." Pharmacoepidemiol Drug Saf **15**(5): 291-303.

Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med. 2012 Apr 19;366(16):1467-76

Ylitalo R, Oksala O, Yla-Herttuala S, Ylitalo P. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. *J Lab Clin Med.* 1994;123(5):769-76.

Yusuf A, Feudjo Tepie M, Kalouche-Khalil L, et al. Effectiveness of bone therapies in routine clinical practice: two retrospective database analyses using US MarketScan and Medicare [abstract]. *Osteoporos Int.* 2016;27(Suppl 1):S79-S548. Abstract P190.

15. Appendices

Appendix A. List of Stand-alone Documents

No.	Document Reference Number	Date	Title
1	*None*		

Appendix B. ENCePP Checklist for Study Protocols

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Doc.Ref. EMA/540136/2009

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

ENCePP Checklist for Study Protocols (Revision 4)

Adopted by the ENCePP Steering Group on 15/10/2018

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) welcomes innovative designs and new methods of research. This Checklist has been developed by ENCePP to stimulate consideration of important principles when designing and writing a pharmacoepidemiological or pharmacovigilance study protocol. The Checklist is intended to promote the quality of such studies, not their uniformity. The user is also referred to the ENCePP Guide on Methodological Standards in Pharmacoepidemiology, which reviews and gives direct electronic access to guidance for research in pharmacoepidemiology and pharmacovigilance.

For each question of the Checklist, the investigator should indicate whether or not it has been addressed in the study protocol. If the answer is "Yes", the section number of the protocol where this issue has been discussed should be specified. It is possible that some questions do not apply to a particular study (for example, in the case of an innovative study design). In this case, the answer 'N/A' (Not Applicable) can be checked and the "Comments" field included for each section should be used to explain why. The "Comments" field can also be used to elaborate on a "No" answer.

This Checklist should be included as an Annex by marketing authorisation holders when submitting the protocol of a non-interventional post-authorisation safety study (PASS) to a regulatory authority (see the Guidance on the format and content of the protocol of non-interventional post-authorisation safety studies). The Checklist is a supporting document and does not replace the format of the protocol for PASS presented in the Guidance and Module VIII of the Good pharmacovigilance practices (GVP).

Study title:

EU PAS Register® number: EMEA/H/C/001120
Study reference number (if applicable):

Section 1: Milestones	**Yes**	**No**	**N/A**	**Section Number**
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection[1]	☒	☐	☐	6
1.1.2 End of data collection[2]	☒	☐	☐	6
1.1.3 Progress report(s)	☐	☐	☒	
1.1.4 Interim report(s)	☐	☐	☒	
1.1.5 Registration in the EU PAS Register®	☒	☐	☐	6
1.1.6 Final report of study results.	☒	☐	☐	6

[1] Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.
[2] Date from which the analytical dataset is completely available.

Comments:

Dates for above timeline will depend on when the protocol is approved by EMA

Section 2: Research question	**Yes**	**No**	**N/A**	**Section Number**
2.1 Does the formulation of the research question and objectives clearly explain:	☒	☐	☐	7
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	☒	☐	☐	7
2.1.2 The objective(s) of the study?	☒	☐	☐	8
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	☒	☐	☐	9.2
2.1.4 Which hypothesis(-es) is (are) to be tested?	☒	☐	☐	7.3
2.1.5 If applicable, that there is no *a priori* hypothesis?	☐	☐	☒	7.2

Comments:

Section 3: Study design	**Yes**	**No**	**N/A**	**Section Number**
3.1 Is the study design described? (e.g. cohort, case-control, cross-sectional, other design)	☒	☐	☐	9.1
3.2 Does the protocol specify whether the study is based on primary, secondary or combined data collection?	☒	☐	☐	9.1
3.3 Does the protocol specify measures of occurrence? (e.g., rate, risk, prevalence)	☒	☐	☐	9.7.2.4
3.4 Does the protocol specify measure(s) of association? (e.g. risk, odds ratio, excess risk, rate ratio, hazard ratio, risk/rate difference, number needed to harm (NNH))	☒	☐	☐	9.7.2.4
3.5 Does the protocol describe the approach for the collection and reporting of adverse events/adverse reactions? (e.g. adverse events that will not be collected in case of primary data collection)	☒	☐	☐	11

Comments:

Section 4: Source and study populations	**Yes**	**No**	**N/A**	**Section Number**
4.1 Is the source population described?	☒	☐	☐	9.4
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period	☒	☐	☐	9.2.1
4.2.2 Age and sex	☒	☐	☐	9.2.3.1
4.2.3 Country of origin	☒	☐	☐	9.4
4.2.4 Disease/indication	☒	☐	☐	9.2.3.1
4.2.5 Duration of follow-up	☒	☐	☐	9.2.6

Section 4: Source and study populations	Yes	No	N/A	Section Number
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	☒	☐	☐	9.2.3

Comments:

Study population is defined based on treatment not disease.

Section 5: Exposure definition and measurement	Yes	No	N/A	Section Number
5.1 Does the protocol describe how the study exposure is defined and measured? (e.g. operational details for defining and categorising exposure, measurement of dose and duration of drug exposure)	☒	☐	☐	9.3.1
5.2 Does the protocol address the validity of the exposure measurement? (e.g. precision, accuracy, use of validation sub-study)	☒	☐	☐	9.9.1
5.3 Is exposure categorised according to time windows?	☒	☐	☐	9.3.1
5.4 Is intensity of exposure addressed? (e.g. dose, duration)	☒	☐	☐	9.7.2.5.4
5.5 Is exposure categorised based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	☒	☐	☐	7
5.6 Is (are) (an) appropriate comparator(s) identified?	☒	☐	☐	7

Comments:

Section 6: Outcome definition and measurement	Yes	No	N/A	Section Number
6.1 Does the protocol specify the primary and secondary (if applicable) outcome(s) to be investigated?	☒	☐	☐	9.3.2
6.2 Does the protocol describe how the outcomes are defined and measured?	☒	☐	☐	9.3.2
6.3 Does the protocol address the validity of outcome measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, use of validation sub-study)	☒	☐	☐	9.3.4
6.4 Does the protocol describe specific outcomes relevant for Health Technology Assessment? (e.g. HRQoL, QALYs, DALYS, health care services utilisation, burden of disease or treatment, compliance, disease management)	☐	☒	☐	

Comments:

This study assesses the risk of cardiovascular and cerebrovascular events

Section 7: Bias	Yes	No	N/A	Section Number
7.1 Does the protocol address ways to measure confounding? (e.g. confounding by indication)	☒	☐	☐	9.7.2.4
7.2 Does the protocol address selection bias? (e.g. healthy user/adherer bias)	☒	☐	☐	9.9.1.3
7.3 Does the protocol address information bias? (e.g. misclassification of exposure and outcomes, time-related bias)	☒	☐	☐	9.9.1.2

Comments:

Section 8: Effect measure modification	Yes	No	N/A	Section Number
8.1 Does the protocol address effect modifiers? (e.g. collection of data on known effect modifiers, sub-group analyses, anticipated direction of effect)	☒	☐	☐	9.7.2.5.1

Comments:

Section 9: Data sources	Yes	No	N/A	Section Number
9.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				9.4
9.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview)	☒	☐	☐	9.4
9.1.2 Outcomes? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics)	☒	☐	☐	9.4
9.1.3 Covariates and other characteristics?	☒	☐	☐	9.4
9.2 Does the protocol describe the information available from the data source(s) on:				
9.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	☒	☐	☐	9.3.1
9.2.2 Outcomes? (e.g. date of occurrence, multiple event, severity measures related to event)	☒	☐	☐	9.3.2
9.2.3 Covariates and other characteristics? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, lifestyle)	☒	☐	☐	9.3.3
9.3 Is a coding system described for:				
9.3.1 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	☒	☐	☐	9.3.1
9.3.2 Outcomes? (e.g. International Classification of Diseases (ICD), Medical Dictionary for Regulatory Activities (MedDRA))	☒	☐	☐	9.3.2
9.3.3 Covariates and other characteristics?	☒	☐	☐	9.3.4
9.4 Is a linkage method between data sources described? (e.g. based on a unique identifier or other)	☐	☐	☒	

Comments:

Section 10: Analysis plan	**Yes**	**No**	**N/A**	**Section Number**
10.1 Are the statistical methods and the reason for their choice described?	☒	☐	☐	9.7.2.3.2 9.7.2.4
10.2 Is study size and/or statistical precision estimated?	☒	☐	☐	9.5
10.3 Are descriptive analyses included?	☒	☐	☐	9.7.2.3.2
10.4 Are stratified analyses included?	☐	☐	☒	
10.5 Does the plan describe methods for analytic control of confounding?	☒	☐	☐	9.9.1.4
10.6 Does the plan describe methods for analytic control of outcome misclassification?	☐	☒	☐	
10.7 Does the plan describe methods for handling missing data?	☐	☒	☐	9.9.4
10.8 Are relevant sensitivity analyses described?	☒	☐	☐	9.7.2.5.4

Comments:

Section 11: Data management and quality control	**Yes**	**No**	**N/A**	**Section Number**
11.1 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	☒	☐	☐	9.6
11.2 Are methods of quality assurance described?	☒	☐	☐	9.6.3
11.3 Is there a system in place for independent review of study results?	☐	☒	☐	

Comments:

Section 12: Limitations	**Yes**	**No**	**N/A**	**Section Number**
12.1 Does the protocol discuss the impact on the study results of:				
12.1.1 Selection bias?	☒	☐	☐	9.9.1.3
12.1.2 Information bias?	☒	☐	☐	9.9.1.2
12.1.3 Residual/unmeasured confounding? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods).	☒	☐	☐	9.7.2.5.3
12.2 Does the protocol discuss study feasibility? (e.g. study size, anticipated exposure uptake, duration of follow-up in a cohort study, patient recruitment, precision of the estimates)	☒	☐	☐	9.5

Comments:

Section 13: Ethical/data protection issues	Yes	No	N/A	Section Number
13.1 Have requirements of Ethics Committee/ Institutional Review Board been described?	☒	☐	☐	10.2
13.2 Has any outcome of an ethical review procedure been addressed?	☐	☐	☒	
13.3 Have data protection requirements been described?	☒	☐	☐	9.8

Comments:

Section 14: Amendments and deviations	Yes	No	N/A	Section Number
14.1 Does the protocol include a section to document amendments and deviations?	☒	☐	☐	5

Comments:

Section 15: Plans for communication of study results	Yes	No	N/A	Section Number
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	☒	☐	☐	13
15.2 Are plans described for disseminating study results externally, including publication?	☒	☐	☐	13

Comments:

This study will be reported to regulatory agencies, no external dissemination is anticipated.

Name of the main author of the protocol: PPD PPD

Date: dd/Month/year 11/March/2019

Signature: PPD PPD

Appendix C. Codes for Exclusion Criteria Paget's Disease of Bone and Diagnosis and Treatment of Cancer

Paget's Disease

	US ICD-9-CM Code	US ICD-10-CM code
Paget's disease of bone	731.0	M88.9

Diagnosis of Cancer

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
140.xx	Lip	C00.-	Malignant neoplasm of lip
141.xx	Tongue	C01.-	Malignant neoplasm of base of tongue
		C02.-	Malignant neoplasm of other and unspecified parts of tongue
142.xx	Major salivary glands	C07.-	Malignant neoplasm of parotid gland
		C08.-	Malignant neoplasm of other and unspecified major salivary glands
143.xx	Gum	C03.-	Malignant neoplasm of gum
144.xx	Floor of mouth	C04.-	Malignant neoplasm of floor of mouth
145.xx	Mouth unspecified	C05.-	Malignant neoplasm of palate
		C06.-	Malignant neoplasm of other and unspecified parts of mouth
146.xx	Oropharynx	C09.-	Malignant neoplasm of tonsil
		C10.-	Malignant neoplasm of oropharynx
147.xx	Nasopharynx	C11.-	Malignant neoplasm of nasopharynx
148.xx	Hypopharynx	C12.-	Malignant neoplasm of pyriform sinus
		C13.-	Malignant neoplasm of hypopharynx
149.xx	Lip other and ill-defined	C14.-	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
150.xx	Esophagus	C15.-	Malignant neoplasm of esophagus
151.xx	Stomach	C16.-	Malignant neoplasm of stomach

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
152.xx	Small intestine	C17.-	Malignant neoplasm of small intestine
153.xx	Colon	C18.-	Malignant neoplasm of colon
209.0 to 209.3	Malignant carcinoid tumors		
154.xx	Rectum	C19.-	Malignant neoplasm of rectosigmoid junction
		C21.-	Malignant neoplasm of anus and anal canal
		C20.-	Malignant neoplasm of rectum
155.xx	Liver	C22.-	Malignant neoplasm of liver and intrahepatic bile ducts
156.xx	Gallbladder & bile ducts	C23.-	Malignant neoplasm of gallbladder
		C24.-	Malignant neoplasm of other and unspecified parts of biliary tract
157.xx	Pancreas	C25.-	Malignant neoplasm of pancreas
158.xx	Retroperitoneum/peritoneum	C48.-	Malignant neoplasm of retroperitoneum and peritoneum
159.xx	Digestive organ/peritoneum other ill-defined	C26.-	Malignant neoplasm of other and ill-defined digestive organs
160.xx	Nasal cavities, middle ear & accessory sinus	C30.-	Malignant neoplasm of nasal cavity and middle ear
		C31.-	Malignant neoplasm of accessory sinuses
161.xx	Larynx	C32.-	Malignant neoplasm of larynx
162.xx	Lung, bronchus & trachea	C33.-	Malignant neoplasm of trachea
		C34.-	Malignant neoplasm of bronchus and lung

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
163.xx	Pleura	C38.-	Malignant neoplasm of heart, mediastinum and pleura
163.xx	Pleura		
		C45.-	Mesothelioma
164.xx	Thymus, heart & mediastinum	C37.-	Malignant neoplasm of thymus
		C38.-	Malignant neoplasm of heart, mediastinum
165.xx	Respiratory, intrathoracic other ill-defined	C39.-	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs
170.xx	Bone and articular cartilage	C40.-	Malignant neoplasm of bone and articular cartilage of limbs
		C41.-	Malignant neoplasm of bone and articular cartilage of other and unspecified sites
171.xx	Connective and other soft tissue	C47.-	Malignant neoplasm of peripheral nerves and autonomic nervous system
		C49.-	Malignant neoplasm of other connective and soft tissue
172.xx	Melanoma	C43.- D03.-	Malignant melanoma of skin Melanoma in situ
174.xx	Female breast	C50.-	Malignant neoplasm of breast
175.xx	Male breast	C50.-	Malignant neoplasm of breast
176.xx	Kaposi sarcoma	C46.-	Kaposi's sarcoma
179	Uterus, part unspecified	C55.-	Malignant neoplasm of uterus, part unspecified
180.xx	Cervix	C53.-	Malignant neoplasm of cervix uteri
181.xx	Placentia	C58.-	Malignant neoplasm of placenta

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
182.xx	Body of uterus	C54.-	Malignant neoplasm of corpus uteri
183.xx	Ovary, fallopian tube, broad ligament, parametrium, round ligament, other specified sites of uterine adnexa	C56.-	Malignant neoplasm of ovary
		C57.-	Malignant neoplasm of unspecified fallopian tube
184.xx	Female genital other and unspecified	C51.-	Malignant neoplasm of vulva
		C52.-	Malignant neoplasm of vagina
		C57.-	Malignant neoplasm of unspecified fallopian tube
185.xx	Prostate	C61.-	Malignant neoplasm of prostate
186.xx	Testis	C62.-	Malignant neoplasm of testis
187.xx	Penis and male other	C60.-	Malignant neoplasm of penis
		C63.-	Malignant neoplasm of other and unspecified male genital organs
188.xx	Bladder	C67.-	Malignant neoplasm of bladder
189.xx	Kidney/Renal	C64.-	Malignant neoplasm of kidney, except renal pelvis
		C65.-	Malignant neoplasm of renal pelvis
		C66.-	Malignant neoplasm of ureter
		C67.-	Malignant neoplasm of bladder
		C68.-	Malignant neoplasm of other and unspecified urinary organs
190.xx	Eye	C69.-	Malignant neoplasm of eye and adnexa

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
191.xx	Brain	C71.-	Malignant neoplasm of brain
192.xx	Malignant neoplasm of other and unspecified parts of nervous system	C70.-	Malignant neoplasm of meninges
		C72.-	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system
193	Malignant neoplasm of thyroid gland	C73.-	Malignant neoplasm of thyroid gland
194.xx	Other Endocrine glands and related structures	C74.-	Malignant neoplasm of adrenal gland
		C75.-	Malignant neoplasm of other endocrine glands and related structures
195.xx	Other and ill-defined sites	C76.-	Malignant neoplasm of other and ill-defined sites
199.xx	Without specification of sites	C80.-	Malignant neoplasm without specification of site
200.xx	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic structure	C83.-	Non-follicular lymphoma
		C85.-	Other specified and unspecified types of non-Hodgkin lymphoma
		C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
		C96.-	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
201.xx	Hodgkin's Lymphoma	C81.-	Hodgkin lymphoma

US ICD-9-CM Codes	US ICD-9-CM Descriptions	US ICD-10-CM Codes	US ICD-10-CM Description
202.xx	Other lymphoid and histiocytic tissue	C82.-	Follicular lymphoma
		C84.-	Mature T/NK-cell lymphomas
		C85.-	Other specified and unspecified types of non-Hodgkin lymphoma
		C96.-	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
		C91.4-	Hairy cell leukemia
202.xx	Other lymphoid and histiocytic tissue	C86.-	Other specified types of T/NK-cell lymphoma
203.xx	Multiple myeloma	C90.- -	Multiple myeloma and malignant plasma cell neoplasms
		C88.2, C88.3, C88.8, C88.9	Other malignant immunoproliferative diseases
204.xx	Lymphoid leukemia	C91.--	Lymphoid Leukemia
205.xx	Myeloid leukemia	C92.-	Myeloid leukemia
206.xx	Monocytic leukemia	C93.-0	Monocytic leukemia
207.xx	Other specified leukemia	C94.-0	Other leukemias of specified cell type
207.xx	Other specified leukemia	D45.-	Polycythemia vera
208.xx	Leukemia unspecified	C95.-0	Leukemia of unspecified cell type
		C96.-	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
196.xx	Secondary and unspecified malignant neoplasm of lymph nodes	C77.-	Secondary and unspecified malignant neoplasm of lymph nodes
197.xx	Secondary malignant neoplasm of respiratory and digestive systems	C78.*	Secondary malignant neoplasm of respiratory and digestive organs
198.xx	Secondary malignant neoplasm of other specified sites	C79.*	Secondary malignant neoplasm of other and unspecified sites

Treatment of Cancer

	Chemotherapy HCPCS
A9523	Supply of radiopharmaceutical therapeutic imaging agent, yttrium 90 ibritumomab tiuxetan, per mci
A9534	Supply of radiopharmaceutical therapeutic imaging agent, i-131 tositumomab, per millicurie
A9543	Yttrium y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
A9544	Iodine i-131 tositumomab, diagnostic, per study dose
A9545	Iodine i-131 tositumomab, therapeutic, per treatment dose
C1081	Supply of radiopharmaceutical therapeutic imaging agent, i-131 tositumomab, per dose
C1083	Supply of radiopharmaceutical therapeutic imaging agent, yttrium 90 ibritumomab tiuxetan, per dose
C1166	Injection, cytarabine liposome, per 10 mg
C1178	Injection, busulfan, per 6 mg
C8953	Chemotherapy administration, intravenous; push technique
C8954	Chemotherapy administration, intravenous; infusion technique, up to one hour
C8955	Chemotherapy administration, intravenous; infusion technique, each additional hour
C9024	Injection, liposomal, daunorubicin and cytarabine, 1mg/2.27mg
C9028	Injection, inotuzumab ozogamicin, 0.1 mg
C9030	Injection, copanlisib, 1 mg
C9038	Injection, MOGAMULIZUMAB-KPKC (Poteligeo), 20 mg/5 mL (4 mg/mL)
C9120	Injection, fulvestrant, per 50 mg
C9205	Injection, oxaliplatin, per 5 mg
C9213	Injection, pemetrexed, per 10 mg
C9214	Bevacizumab
C9257	INJECTION, BEVACIZUMAB, 0.25 mg
C9289	INJECTION, ASPARAGINASE ERWINIA CHRYSANTHEMI, 1,000 INTERNATIONAL UNITS (I. U.)

C9407	IOBENGUANE IODINE-131, diagnostic, 1 millicurie IV injection + IV infusion
C9408	IOBENGUANE IODINE-131, therapeutic, 1 millicurie IV injection + IV infusion
C9414	Etoposide, oral, brand name, 50 mg
C9415	Doxorubicin hcl, brand name, 10 mg
C9417	Bleomycin sulfate, brand name, 15 units
C9418	Cisplatin, powder or s0lution, brand name, per 10 mg
C9419	Injection, cladribine, brand name, per 1 mg
C9420	Cyclophosphamide, brand name, 100 mg
C9421	Cyclophosphamide, lyophilized, brand name, 100 mg
C9422	Cytarabine, brand name, 100 mg
C9423	Dacarbazine, brand name, 100 mg
C9424	Daunorubicin, brand name, 10 mg
C9425	Etoposide, brand name, 10 mg
C9426	Floxuridine, brand name, 500 mg
C9427	Ifosfamide, brand name, 1 gm
C9428	Mesna, brand name, 200 mg
C9429	Idarubicin hydrochloride, brand name, 5 mg
C9431	Paclitaxel, brand name, 30 mg
C9432	Mitomycin, brand name, 5 mg
C9433	Thiotepa, brand name, 15 mg
C9437	Carmustine, brand name, 100 mg
C9440	Vinorelbine tartrate, brand name, per 10 mg
C9467	Injection, rituximab and hyaluronidase, 10mg
G0355	Chemotherapy administration, subcutaneous or intramuscular non-hormonal antineoplastic
G0359	Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug
G0360	Chemotherapy administration, intravenous infusion technique; each additional hour, one to eight (8) hours
G0361	Initiation of prolonged chemotherapy infusion (more than

	eight hours), requiring use of a portable or implantable pump
G0362	Each additional sequential infusion (different substance/drug), up to one hour
G3001	Administration and supply of tositumomab, 450 mg
J0594	Injection, busulfan, per 1 mg
J8510	BUSULFAN; ORAL, 2 MG
J8520	CAPECITABINE, ORAL, 150 MG
J8521	CAPECITABINE, ORAL, 500 MG
J8530	CYCLOPHOSPHAMIDE; ORAL, 25 MG
J8560	ETOPOSIDE; ORAL, 50 MG
J8565	Gefitinib, oral, 250 mg
J8600	MELPHALAN; ORAL, 2 MG
J8700	TEMOZOLOMIDE, ORAL, 5 MG
J8705	Topotecan, oral, 0.25mg
J8999	Prescription drug, oral, chemotherapeutic, nos
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG
J9001	INJECTION, DOXORUBICIN HYDROCHLORIDE, ALL LIPID FORMULATIONS, 10 MG
J9002	INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, DOXIL, 10MG
J9010	INJECTION, ALEMTUZUMAB, 10 MG
J9015	INJECTION, ALDESLEUKIN, PER SINGLE USE VIAL
J9017	INJECTION, ARSENIC TRIOXIDE, 1 MG
J9020	INJECTION, ASPARAGINASE, 10,000 UNITS
J9025	INJECTION, AZACITIDINE, 1 MG
J9027	INJECTION, CLOFARABINE, 1 MG
J9031	BCG (INTRAVESICAL) PER INSTILLATION
J9033	INJECTION, BENDAMUSTINE HCL, 1 MG
J9035	INJECTION, BEVACIZUMAB, 10 MG
J9040	INJECTION, BLEOMYCIN SULFATE, 15 UNITS
J9041	INJECTION, BORTEZOMIB, 0.1 MG

J9045	INJECTION, CARBOPLATIN, 50 MG
J9050	INJECTION, CARMUSTINE, 100 MG
J9055	Injection, cetuximab, 10 mg
J9057	INJECTION, COPANLISIB, 1 MG
J9060	CISPLATIN, POWDER OR S0LUTION, PER 10 MG
J9062	CISPLATIN, 50 MG
J9065	INJECTION, CLADRIBINE, PER 1 MG
J9070	CYCLOPHOSPHAMIDE, 100 MG
J9080	CYCLOPHOSPHAMIDE, 200 MG
J9090	CYCLOPHOSPHAMIDE, 500 MG
J9091	CYCLOPHOSPHAMIDE, 1.0 GRAM
J9092	CYCLOPHOSPHAMIDE, 2.0 GRAM
J9093	CYCLOPHOSPHAMIDE, LYOPHILIZED, 100 MG
J9094	CYCLOPHOSPHAMIDE, LYOPHILIZED, 200 MG
J9095	CYCLOPHOSPHAMIDE, LYOPHILIZED, 500 MG
J9096	CYCLOPHOSPHAMIDE, LYOPHILIZED, 1.0 GRAM
J9097	CYCLOPHOSPHAMIDE, LYOPHILIZED, 2.0 GRAM
J9098	INJECTION, CYTARABINE LIPOSOME, 10 MG
J9100	INJECTION, CYTARABINE, 100 MG
J9110	INJECTION, CYTARABINE, 500 MG
J9120	INJECTION, DACTINOMYCIN, 0.5 MG
J9130	DACARBAZINE, 100 MG
J9140	DACARBAZINE, 200 MG
J9150	INJECTION, DAUNORUBICIN, 10 MG
J9151	INJECTION, DAUNORUBICIN CITRATE, LIPOSOMAL FORMULATION, 10 MG
J9153	INJECTION, LIPOSOMAL, DAUNORUBICIN AND CYTARABINE, 1MG/2.27MG
J9160	Injection, denileukin diftitox, 300 micrograms
J9165	Injection, diethylstilbestrol diphosphate, 250 mg
J9170	INJECTION, DOCETAXEL, 20 MG

J9171	Injection, docetaxel, 1 mg
J9175	Injection, elliotts' b solution, 1 ml
J9178	INJECTION, EPIRUBICIN HCL, 2 MG
J9181	INJECTION, ETOPOSIDE, 10 MG
J9182	ETOPOSIDE, 100 MG
J9185	INJECTION, FLUDARABINE PHOSPHATE, 50 MG
J9190	INJECTION, FLUOROURACIL, 500 MG
J9200	INJECTION, FLOXURIDINE, 500 MG
J9201	INJECTION, GEMCITABINE HYDROCHLORIDE, 200 MG
J9202	GOSERELIN ACETATE IMPLANT, PER 3.6 MG
J9206	INJECTION, IRINOTECAN, 20 MG
J9207	INJECTION, IXABEPILONE, 1 MG
J9208	INJECTION, IFOSFAMIDE, 1 GRAM
J9209	INJECTION, MESNA, 200 MG
J9211	INJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG
J9217	LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG
J9218	LEUPROLIDE ACETATE, PER 1 MG
J9219	LEUPROLIDE ACETATE IMPLANT, 65 MG
J9229	INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG
J9230	INJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG
J9245	INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG
J9261	INJECTION, NELARABINE, 50 MG
J9263	INJECTION, OXALIPLATIN, 0.5 MG
J9264	INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG
J9265	INJECTION, PACLITAXEL, 30 MG
J9266	INJECTION, PEGASPARGASE, PER SINGLE DOSE VIAL
J9268	INJECTION, PENTOSTATIN, 10 MG
J9270	INJECTION, PLICAMYCIN, 2.5 MG
J9280	MITOMYCIN, 5 MG

J9290	MITOMYCIN, 20 MG
J9291	MITOMYCIN, 40 MG
J9293	INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG
J9300	INJECTION, GEMTUZUMAB OZOGAMICIN, 5 MG
J9303	Injection, panitumumab, 10 mg
J9305	INJECTION, PEMETREXED, 10 MG
J9310	INJECTION, RITUXIMAB, 100 MG
J9311	INJECTION, RITUXIMAB AND HYALURONIDASE, 10MG
J9320	INJECTION, STREPTOZOCIN, 1 GRAM
J9328	Injection, temozolomide, 1 mg
J9330	INJECTION, TEMSIROLIMUS, 1 MG
J9340	INJECTION, THIOTEPA, 15 MG
J9350	INJECTION, TOPOTECAN, 4 MG
J9351	INJECTION, TOPOTECAN, 0.1 MG
J9355	INJECTION, TRASTUZUMAB, 10 MG
J9357	INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG
J9360	INJECTION, VINBLASTINE SULFATE, 1 MG
J9370	VINCRISTINE SULFATE, 1 MG
J9375	VINCRISTINE SULFATE, 2 MG
J9380	VINCRISTINE SULFATE, 5 MG
J9390	INJECTION, VINORELBINE TARTRATE, 10 MG
J9395	INJECTION, FULVESTRANT, 25 MG
J9600	INJECTION, PORFIMER SODIUM, 75 MG
J9999	NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS
Q0083	Chemotherapy administration by other than infusion technique only (e.g. subcutaneous, intramuscluar, etc), per visit
Q0084	Chemotherapy administration by infusion technique only, per visit
Q0085	Chemotherapy administration by both infusion technique and other technique(s), per visit
Q2017	INJECTION, TENIPOSIDE, 50 MG
Q2024	INJECTION, BEVACIZUMAB, 0.25 mg

Q2025	FLUDARABINE PHOSPHATE, ORAL, 1 MG
Q2041	AXICABTAGENE CILOLEUCEL, suspension for intravenous infusion
Q2042	TISAGENLECLEUCEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND...PER DOSE
Q2048	INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, DOXIL, 10 MG
Q2049	INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG
S0087	Alemtuzumab injection, 30 mg.
S0088	IMATINIB, 100 MG
S0108	MERCAPTOPURINE, ORAL, 50 MG
S0115	Bortezomib, 3.5 mg.
S0116	BEVACIZUMAB, 100 MG
S0168	INJECTION, AZACITIDINE, 100 MG
S0172	CHLORAMBUCIL, ORAL, 2MG
S0178	LOMUSTINE, ORAL, 10MG
S0182	PROCARBAZINE HYDROCHLORIDE, ORAL, 50MG
S1016	NON-PVC (POLYVINYL CHLORIDE) INTRAVENOUS ADMINISTRATION SET, FOR USE WITH DRUGS THAT ARE NOT STABLE IN PVC E.G. PACLITAXEL
S9329	Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equiptment (drugs and nursing visits coded seperately), per diem
S9330	Home infusion therapy, continuous chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equiptment (drugs and nursing visits coded deparately), per diem
S9331	Home infusion therapy, intermittent chemotherapy infusion;

		administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded seperately), per diem
S3722		DOSE OPTIMIZATION BY AREA UNDER THE CURVE (AUC) ANALYSIS, FOR INFUSIONAL 5-FLUOROURACIL
		Chemotherapy revenue code
	280	Oncology (Chemotherapy)
	289	Other Oncology
	331	Chemotherapy/Injected
	332	Chemotherapy/Oral
	335	Chemotherapy IV
		Chemotherapy CPT-4
96401		CHEMOTHERAPY ADMINISTRATION, SUBCUTANEOUS OR INTRAMUSCULAR; NON-HORMONAL ANTI-NEOPLASTIC
96402		CHEMOTHERAPY ADMINISTRATION, SUBCUTANEOUS OR INTRAMUSCULAR; HORMONAL ANTI-NEOPLASTIC
96405		CHEMOTHERAPY ADMINISTRATION; INTRALESIONAL, UP TO AND INCLUDING 7 LESIONS
96406		CHEMOTHERAPY ADMINISTRATION; INTRALESIONAL, MORE THAN 7 LESIONS
96409		CHEMOTHERAPY ADMINISTRATION; INTRAVENOUS, PUSH TECHNIQUE, SINGLE OR INITIAL SUBSTANCE/DRUG
96411		CHEMOTHERAPY ADMINISTRATION; INTRAVENOUS, PUSH TECHNIQUE, EACH ADDITIONAL SUBSTANCE/DRUG (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

96413	CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE; UP TO 1 HOUR, SINGLE OR INITIAL SUBSTANCE/DRUG
96415	CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE; EACH ADDITIONAL HOUR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
96416	CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE; INITIATION OF PROLONGED CHEMOTHERAPY INFUSION (MORE THAN 8 HOURS), REQUIRING USE OF A PORTABLE OR IMPLANTABLE PUMP
96417	CHEMOTHERAPY ADMINISTRATION, INTRAVENOUS INFUSION TECHNIQUE; EACH ADDITIONAL SEQUENTIAL INFUSION (DIFFERENT SUBSTANCE/DRUG), UP TO 1 HOUR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
96420	CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; PUSH TECHNIQUE
96422	CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; INFUSION TECHNIQUE, UP TO 1 HOUR
96423	CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; INFUSION TECHNIQUE, EACH ADDITIONAL HOUR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
96425	CHEMOTHERAPY ADMINISTRATION, INTRA-ARTERIAL; INFUSION TECHNIQUE, INITIATION OF PROLONGED INFUSION (MORE

	THAN 8 HOURS), REQUIRING THE USE OF A PORTABLE OR IMPLANTABLE PUMP
96440	CHEMOTHERAPY ADMINISTRATION INTO PLEURAL CAVITY, REQUIRING AND INCLUDING THORACENTESIS
96445	CHEMOTHERAPY ADMINISTRATION INTO PERITONEAL CAVITY, REQUIRING AND INCLUDING PERITONEOCENTESIS
96450	CHEMOTHERAPY ADMINISTRATION, INTO CNS (EG, INTRATHECAL), REQUIRING AND INCLUDING SPINAL PUNCTURE
96542	CHEMOTHERAPY INJECTION, SUBARACHNOID OR INTRAVENTRICULAR VIA SUBCUTANEOUS RESERVOIR, SINGLE OR MULTIPLE AGENTS
96549	UNLISTED CHEMOTHERAPY PROCEDURE

	Chemotherapy ICD Procedure codes
99.25	Injection or infusion of cancer chemotherapeutic substance
0.15	High-dose infusion interleukin-2 [IL-2]
0.1	Implantation of chemotherapeutic agent
99.28	Injection or infusion of biological response modifier [BRM] as an antineoplastic agent
17.7	Intravenous infusion of clofarabine
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous

	Approach, New Technology Group 1
3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening

3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening
3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach

3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening
3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach
3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening
3E00X0M	Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach
3E0130M	Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach

3E0230M	Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
3E0330M	Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E0430M	Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
3E0530M	Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
3E0630M	Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach
3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach
	Chemotherapy ICD V-Codes
V07.3	Other prophylactic chemotherapy

V07.31	Need for prophylactic fluoride administration
V07.39	Need for other prophylactic chemotherapy
V58.1	Encounter for chemotherapy and immunotherapy for neoplastic conditions
V58.11	Encounter for antineoplastic chemotherapy
V58.12	Encounter for antineoplastic immunotherapy
V66.2	Convalencense and palliative care following chemotherapy
V67.2	Exam following chemotherapy
Z29.3	Encounter for prophylactic fluoride administration
Z29.8	Encounter for other specified prophylactic measures
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy
Z51.89	Encounter for other specified aftercare
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm
Z09	Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm

	Chemotherapy (Hormone) HCPCS
J0128	Abarelix
S0165	Abarelix
S0170	Anastrozole
J9165	Diethylstilbestrol
C9439	Diethylstilbestrol
S0156	Exemestane
S0175	Flutamide
J9395	Fulvestran
J9202	Goserelin
C9430	Leuprolide
J1950	Leuprolide
J9217	Leuprolide
J9218	Leuprolide
J9219	Leuprolide
S0179	Megestrol
S0187	Tamoxifen

J3315	Triptorelin pamoate
S9560	Goserelin
G8381	Tamoxifen
J9155	Injection, degarelix, 1 mg
J9225	HISTRELIN IMPLANT (VANTAS), 50 MG
J9226	HISTRELIN IMPLANT (SUPPRELIN LA), 50 MG

	Radiation Revenue code
330	Radiology - Therapeutic and/or Chemotherapy Administration General Classification
331	Radiology - Therapeutic Chemotherapy - Injected
331	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Administration - Injected
331	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Admin - Injected
332	Radiology - Therapeutic Chemotherapy - Oral
332	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Administration - Oral
332	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Admin - Oral
333	Radiology - Therapeutic and/or Chemotherapy Administration Radiation Therapy
333	Radiology - Therapeutic Radiation Therapy
335	Radiology - Therapeutic Chemotherapy - IV
335	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Administration - IV
335	Radiology - Therapeutic and/or Chemotherapy Administration Chemotherapy Admin - IV
339	Radiology - Therapeutic and/or Chemotherapy Administration Other Radiology - Therapeutic

	Radiation HCPCS
C9725	Placement of endorectal intracavitary applicator for high intensity brachytherapy
C9726	Placement and removal (if performed) of applicator into breast for radiation therapy
C1715	Brachytherapy needle
C1716	Brachytherapy source, gold 198, per source
C1717	Brachytherapy source, high dose rate iridium 192, per source
C1718	Brachytherapy source, iodine 125, per source
C1719	Brachytherapy source, nonhigh dose rate iridium 192, per source
C1720	Brachytherapy source, palladium 103, per source
C2616	Brachytherapy source, yttrium-90, per source
C2632	Brachytherapy solution, iodine-125, per mci
C2633	Brachytherapy source, cesium-131, per source

C2634	Brachytherapy source, high-activity, Iodine-125, greater than 1.01 mCi (NIST), per source
C2635	Brachytherapy source, high-activity, Paladium-103, greater than 2.2 mCi (NIST), per source
C2636	Brachytherapy linear source, paladium-103, per 1 mm
C2637	Brachytherapy source, non-stranded, ytterbium-169, per source
C2638	Brachytherapy source, stranded, iodine-125, per source
C2639	Brachytherapy source, non-stranded, iodine-125, per source
C2640	Brachytherapy source, stranded, palladium-103, per source
C2641	Brachytherapy source, non-stranded, palladium-103, per source
C2642	Brachytherapy source, stranded, cesium-131, per source
C2643	Brachytherapy source, non-stranded, cesium-131, per source
C2698	Brachytherapy source, stranded, not otherwise specified, per source
C2699	Brachytherapy source, non-stranded, not otherwise specified, per source
Q3001	Radioelements for brachytherapy, any type, each
S8049	Intraoperative radiation therapy (single administration)
G0173	Linear accelerator based stereotactic radiosurgery, complete course of therapy in 1 session
G0251	Linear accelerator based stereotactic radiosurgery, delivery, all lesions, per session, maximum 5 sessions per course of treatment
G0339	Image guided, robotic linear accelerator based stereotactic radiosurgery, complete course of therapy in one session, or first session of fractional treatment
G0340	Image guided, robotic linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, 2nd -5th sessions, max 5
S2095	Transcatheter Occlusion Or Embolization For Tumor Destruction, Percutaneous, Any Method, Using Yttrium-90 Microspheres
S8030	Scleral Application Of Tantalum Ring(S) For Localization Of Lesions For Proton Beam
	Radiation CPT

0073T	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session
0082T	Stereotactic body radiation therapy, treatment delivery, one or more treatment areas, per day
0083T	Stereotactic body radiation therapy, treatment management, per day
0182T	High dose rate electronic brachytherapy, per fraction
77261	Therapeutic radiology treatment planning; simple
77262	Therapeutic radiology treatment planning; intermediate
77263	Therapeutic radiology treatment planning; complex
77280	Therapeutic radiology simulation-aided field setting; simple
77285	Therapeutic radiology simulation-aided field setting; simple
77290	Therapeutic radiology simulation-aided field setting; complex
77295	Therapeutic radiology simulation-aided field setting; 3-dimensional
77299	Unlisted procedure, therapeutic radiology clinical treatment planning
77371	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based
77372	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based

77373	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services
77401	Radiation treatment delivery, superficial and/or ortho voltage
77402	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; up to 5 MeV
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater
77407	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks; up to 5 MeV
77408	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks; 6-10 MeV

77409	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks; 11-19 MeV
77411	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater
77412	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 MeV
77413	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV
77414	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV
77416	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater
77417	Therapeutic radiology port film(s)

77418	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
77421	Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy
77422	High energy neutron radiation treatment delivery; single treatment area using a single port or parallel-opposed ports with no blocks or simple blocking
77423	High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)
77427	Radiation treatment management, five treatments
77431	Radiation therapy management with complete course of therapy consisting of one or two fractions only
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of one session)
77435	Stereotactic body radiation therapy, treatment management, per treatment course, to one or more lesions, including image guidance, entire course not to exceed 5 fractions
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral, endocavitary or intraoperative cone irradiation)

77499	Unlisted procedure, therapeutic radiology treatment management
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex
77750	Infusion or instillation of radioelement solution (includes 3 months follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77776	Interstitial radiation source application; simple
77777	Interstitial radiation source application; intermediate
77778	Interstitial radiation source application; complex
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels

77789	Surface application of radiation source
77790	Supervision, handling, loading of radiation source
77799	Unlisted procedure, clinical brachytherapy
S8049	Intraoperative radiation therapy (single administration)
77600-77620	Hyperthermia codes are used as an adjunct to radiation therapy or chemotherapy & are coded separately.
19296	Placement of radiotherapy afterloading balloon catheter into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; on date separate from partial mastectomy
19297	Placement of radiotherapy afterloading balloon catheter into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary
19298	Placement of radiotherapy afterloading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance
31643	Bronchoscopy (rigid or flexible); with placement of catheter(s) for intracavitary radioelement application

55875 Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy

55876 Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple

55920 Placement of needles or catheters inot pelvic organs and/or genitalia (except prostate) for subsequent interstitial radioelement application

57155 Insertion of intrauterine tandems and/or vaginal ovoids for clinical brachytherapy

58346 Insertion of Heyman capsules for clinical brachytherapy

61796 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion

61797 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, simple (List separately in addition to code for primary procedure)

61798 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion

61799 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, complex (List separately in addition to code for primary procedure)

61800	Application of stereotactic headframe for stereotactic radiosurgery (List separately in addition to code for primary procedure)
63620	Stereotactic radiosurgery (partical beam, gamma ray, or linear accelerator); 1 spinal lesion
63621	Stereotactic radiosurgery (partical beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)
77300	Basic radiation dosimetry calculation
77301	Intensity modulated radiotherapy plan
77305	Simple teletherapy, isodose plan
77310	Intermediate teletherapy, isodose plan
77315	Complex teletherapy, isodose plan
77321	Special teletherapy plan
77326	Simple brachytherapy isodose plan
77327	Intermediate brachytherapy isodose plan
77328	Complex brachytherapy isodose plan
77331	Special dosimetry, prescribed by treating phys
77332	Design/construction simple treatment devices
77333	Design/construction intermed treatment devices
77334	Design/construction complex treatment devices
77336	Cont medical radiation physics consult, per week
77338	Design and Construction of Multileaf Collimator (MLC) Device(s)

77370	Special medical radiation physics consultation
77469	Intraoperative radiation treatment management
79005	Radiopharmaceutical Therapy by oral administration
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session

Radiation ICD Procedure codes	
92.2	Injection Or Infusion Of Other Therapeutic Or Prophylactic Substance
92.3	Stereotactic radiosurgery, not otherwise specified
92.31	Single source photon radiosurgery
92.32	Multi-source photon radiosurgery
92.33	Particulate radiosurgery
92.39	Stereotactic radiosurgery
92.41	Intra-operative electron radiation therapy
99.85	Hyperthermia for treatment of cancer
D020DZZ	Stereotactic Other Photon Radiosurgery of Brain
D021DZZ	Stereotactic Other Photon Radiosurgery of Brain Stem
D027DZZ	Stereotactic Other Photon Radiosurgery of Peripheral Nerve
DG20DZZ	Stereotactic Other Photon Radiosurgery of Pituitary Gland
D020JZZ	Stereotactic Gamma Beam Radiosurgery of Brain
D027JZZ	Stereotactic Gamma Beam Radiosurgery of Peripheral Nerve
DG20JZZ	Stereotactic Gamma Beam Radiosurgery of Pituitary Gland
D020HZZ	Stereotactic Particulate Radiosurgery of Brain
D021HZZ	Stereotactic Particulate Radiosurgery of Brain Stem
D027HZZ	Stereotactic Particulate Radiosurgery of Peripheral Nerve
DG20HZZ	Stereotactic Particulate Radiosurgery of Pituitary Gland
D0003Z0	Beam Radiation of Brain using Electrons, Intraoperative
D0013Z0	Beam Radiation of Brain Stem using Electrons, Intraoperative
D0063Z0	Beam Radiation of Spinal Cord using Electrons, Intraoperative
D0073Z0	Beam Radiation of Peripheral Nerve using Electrons, Intraoperative
D7003Z0	Beam Radiation of Bone Marrow using Electrons, Intraoperative

D7013Z0	Beam Radiation of Thymus using Electrons, Intraoperative
D7023Z0	Beam Radiation of Spleen using Electrons, Intraoperative
D7033Z0	Beam Radiation of Neck Lymphatics using Electrons, Intraoperative
D7043Z0	Beam Radiation of Axillary Lymphatics using Electrons, Intraoperative
D7053Z0	Beam Radiation of Thorax Lymphatics using Electrons, Intraoperative
D7063Z0	Beam Radiation of Abdomen Lymphatics using Electrons, Intraoperative
D7073Z0	Beam Radiation of Pelvis Lymphatics using Electrons, Intraoperative
D7083Z0	Beam Radiation of Inguinal Lymphatics using Electrons, Intraoperative
D8003Z0	Beam Radiation of Eye using Electrons, Intraoperative
D9003Z0	Beam Radiation of Ear using Electrons, Intraoperative
D9013Z0	Beam Radiation of Nose using Electrons, Intraoperative
D9033Z0	Beam Radiation of Hypopharynx using Electrons, Intraoperative
D9043Z0	Beam Radiation of Mouth using Electrons, Intraoperative
D9053Z0	Beam Radiation of Tongue using Electrons, Intraoperative
D9063Z0	Beam Radiation of Salivary Glands using Electrons, Intraoperative
D9073Z0	Beam Radiation of Sinuses using Electrons, Intraoperative
D9083Z0	Beam Radiation of Hard Palate using Electrons, Intraoperative
D9093Z0	Beam Radiation of Soft Palate using Electrons, Intraoperative
D90B3Z0	Beam Radiation of Larynx using Electrons, Intraoperative
D90D3Z0	Beam Radiation of Nasopharynx using Electrons, Intraoperative
D90F3Z0	Beam Radiation of Oropharynx using Electrons, Intraoperative
DB003Z0	Beam Radiation of Trachea using Electrons, Intraoperative
DB013Z0	Beam Radiation of Bronchus using Electrons, Intraoperative
DB023Z0	Beam Radiation of Lung using Electrons, Intraoperative
DB053Z0	Beam Radiation of Pleura using Electrons, Intraoperative
DB063Z0	Beam Radiation of Mediastinum using Electrons, Intraoperative
DB073Z0	Beam Radiation of Chest Wall using Electrons, Intraoperative
DB083Z0	Beam Radiation of Diaphragm using Electrons, Intraoperative
DD003Z0	Beam Radiation of Esophagus using Electrons, Intraoperative

DD013Z0	Beam Radiation of Stomach using Electrons, Intraoperative
DD023Z0	Beam Radiation of Duodenum using Electrons, Intraoperative
DD033Z0	Beam Radiation of Jejunum using Electrons, Intraoperative
DD043Z0	Beam Radiation of Ileum using Electrons, Intraoperative
DD053Z0	Beam Radiation of Colon using Electrons, Intraoperative
DD073Z0	Beam Radiation of Rectum using Electrons, Intraoperative
DF003Z0	Beam Radiation of Liver using Electrons, Intraoperative
DF013Z0	Beam Radiation of Gallbladder using Electrons, Intraoperative
DF023Z0	Beam Radiation of Bile Ducts using Electrons, Intraoperative
DF033Z0	Beam Radiation of Pancreas using Electrons, Intraoperative
DG003Z0	Beam Radiation of Pituitary Gland using Electrons, Intraoperative
DG013Z0	Beam Radiation of Pineal Body using Electrons, Intraoperative
DG023Z0	Beam Radiation of Adrenal Glands using Electrons, Intraoperative
DG043Z0	Beam Radiation of Parathyroid Glands using Electrons, Intraoperative
DG053Z0	Beam Radiation of Thyroid using Electrons, Intraoperative
DH023Z0	Beam Radiation of Face Skin using Electrons, Intraoperative
DH033Z0	Beam Radiation of Neck Skin using Electrons, Intraoperative
DH043Z0	Beam Radiation of Arm Skin using Electrons, Intraoperative
DH063Z0	Beam Radiation of Chest Skin using Electrons, Intraoperative
DH073Z0	Beam Radiation of Back Skin using Electrons, Intraoperative
DH083Z0	Beam Radiation of Abdomen Skin using Electrons, Intraoperative
DH093Z0	Beam Radiation of Buttock Skin using Electrons, Intraoperative
DH0B3Z0	Beam Radiation of Leg Skin using Electrons, Intraoperative
DM003Z0	Beam Radiation of Left Breast using Electrons, Intraoperative
DM013Z0	Beam Radiation of Right Breast using Electrons, Intraoperative
DP003Z0	Beam Radiation of Skull using Electrons, Intraoperative
DP023Z0	Beam Radiation of Maxilla using Electrons, Intraoperative
DP033Z0	Beam Radiation of Mandible using Electrons, Intraoperative

DP043Z0	Beam Radiation of Sternum using Electrons, Intraoperative
DP053Z0	Beam Radiation of Rib(s) using Electrons, Intraoperative
DP063Z0	Beam Radiation of Humerus using Electrons, Intraoperative
DP073Z0	Beam Radiation of Radius/Ulna using Electrons, Intraoperative
DP083Z0	Beam Radiation of Pelvic Bones using Electrons, Intraoperative
DP093Z0	Beam Radiation of Femur using Electrons, Intraoperative
DP0B3Z0	Beam Radiation of Tibia/Fibula using Electrons, Intraoperative
DP0C3Z0	Beam Radiation of Other Bone using Electrons, Intraoperative
DT003Z0	Beam Radiation of Kidney using Electrons, Intraoperative
DT013Z0	Beam Radiation of Ureter using Electrons, Intraoperative
DT023Z0	Beam Radiation of Bladder using Electrons, Intraoperative
DT033Z0	Beam Radiation of Urethra using Electrons, Intraoperative
DU003Z0	Beam Radiation of Ovary using Electrons, Intraoperative
DU013Z0	Beam Radiation of Cervix using Electrons, Intraoperative
DU023Z0	Beam Radiation of Uterus using Electrons, Intraoperative
DV003Z0	Beam Radiation of Prostate using Electrons, Intraoperative
DV013Z0	Beam Radiation of Testis using Electrons, Intraoperative
DW013Z0	Beam Radiation of Head and Neck using Electrons, Intraoperative
DW023Z0	Beam Radiation of Chest using Electrons, Intraoperative
DW033Z0	Beam Radiation of Abdomen using Electrons, Intraoperative
DW043Z0	Beam Radiation of Hemibody using Electrons, Intraoperative
DW053Z0	Beam Radiation of Whole Body using Electrons, Intraoperative
DW063Z0	Beam Radiation of Pelvic Region using Electrons, Intraoperative
DWY18ZZ	Hyperthermia of Head and Neck
DWY28ZZ	Hyperthermia of Chest
DWY38ZZ	Hyperthermia of Abdomen
DWY48ZZ	Hyperthermia of Hemibody
DWY58ZZ	Hyperthermia of Whole Body
DWY68ZZ	Hyperthermia of Pelvic Region
0JHD3HZ	Insertion of Contraceptive Device into Right Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach
0JHF3HZ	Insertion of Contraceptive Device into Left Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach

0JHG3HZ	Insertion of Contraceptive Device into Right Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach
0JHH3HZ	Insertion of Contraceptive Device into Left Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach
0JHL3HZ	Insertion of Contraceptive Device into Right Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach
0JHM3HZ	Insertion of Contraceptive Device into Left Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach
3E00X0M	Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach
3E00XGC	Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach
3E00XNZ	Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach
3E0130M	Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach
3E01329	Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach
3E0133Z	Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach
3E013GC	Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach
3E013NZ	Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach
3E013VJ	Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach
3E0230M	Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach
3E02329	Introduction of Other Anti-infective into Muscle, Percutaneous Approach
3E0233Z	Introduction of Anti-inflammatory into Muscle, Percutaneous Approach
3E023NZ	Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
3E0330M	Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
3E0333Z	Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach
3E033FZ	Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach
3E033HZ	Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach

3E033KZ	Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach
3E033NZ	Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach
3E033PZ	Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach
3E033RZ	Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach
3E033VJ	Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach
3E033WK	Introduction of Immunostimulator into Peripheral Vein, Percutaneous
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
3E0430M	Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach
3E0433Z	Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach
3E043FZ	Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach
3E043HZ	Introduction of Radioactive Substance into Central Vein, Percutaneous Approach
3E043KZ	Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach
3E043NZ	Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach
3E043PZ	Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach
3E043RZ	Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach
3E043VJ	Introduction of Other Hormone into Central Vein, Percutaneous Approach
3E043WK	Introduction of Immunostimulator into Central Vein, Percutaneous
3E050TZ	Introduction of Destructive Agent into Peripheral Artery, Open Approach
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
3E0530M	Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach
3E0533Z	Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach
3E053FZ	Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach
3E053HZ	Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach
3E053KZ	Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach

3E053NZ	Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach
3E053PZ	Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach
3E053RZ	Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach
3E053TZ	Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach
3E053VJ	Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach
3E053WK	Introduction of Immunostimulator into Peripheral Artery, Percutaneous
3E060TZ	Introduction of Destructive Agent into Central Artery, Open Approach
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
3E0630M	Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach
3E0633Z	Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach
3E063FZ	Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
3E063HZ	Introduction of Radioactive Substance into Central Artery, Percutaneous Approach
3E063NZ	Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach
3E063PZ	Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach
3E063RZ	Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach
3E063TZ	Introduction of Destructive Agent into Central Artery, Percutaneous Approach
3E063VJ	Introduction of Other Hormone into Central Artery, Percutaneous Approach
3E063WK	Introduction of Immunostimulator into Central Artery, Percutaneous
3E083PZ	Introduction of Platelet Inhibitor into Heart, Percutaneous Approach
3E0933Z	Introduction of Anti-inflammatory into Nose, Percutaneous Approach
3E093GC	Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach
3E093TZ	Introduction of Destructive Agent into Nose, Percutaneous Approach
3E097GC	Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
3E097TZ	Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening
3E09XTZ	Introduction of Destructive Agent into Nose, External Approach

3E0B33Z	Introduction of Anti-inflammatory into Ear, Percutaneous Approach
3E0C33Z	Introduction of Anti-inflammatory into Eye, Percutaneous Approach
3E0D33Z	Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach
3E0D3GC	Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach
3E0D3TZ	Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach
3E0D7GC	Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
3E0D7TZ	Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening
3E0DXTZ	Introduction of Destructive Agent into Mouth and Pharynx, External Approach
3E0E33Z	Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach
3E0F33Z	Introduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach
3E0G33Z	Introduction of Anti-inflammatory into Upper GI, Percutaneous Approach
3E0G3TZ	Introduction of Destructive Agent into Upper GI, Percutaneous Approach
3E0G7TZ	Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening
3E0G8TZ	Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
3E0H33Z	Introduction of Anti-inflammatory into Lower GI, Percutaneous Approach
3E0H3GC	Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach
3E0H3TZ	Introduction of Destructive Agent into Lower GI, Percutaneous Approach
3E0H7TZ	Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening
3E0H8TZ	Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
3E0J33Z	Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach
3E0K33Z	Introduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach
3E0K3TZ	Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach
3E0K7GC	Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening
3E0K7TZ	Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening
3E0K8GC	Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

3E0K8TZ	Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
3E0L33Z	Introduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach
3E0M33Z	Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach
3E0N33Z	Introduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach
3E0N7GC	Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening
3E0N7TZ	Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening
3E0N8GC	Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
3E0N8TZ	Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
3E0P33Z	Introduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach
3E0P3GC	Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach
3E0Q03Z	Introduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach
3E0Q33Z	Introduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach
3E0R33Z	Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach
3E0S33Z	Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach
3E0T33Z	Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach
3E0U33Z	Introduction of Anti-inflammatory into Joints, Percutaneous Approach
3E0V33Z	Introduction of Anti-inflammatory into Bones, Percutaneous Approach
3E0W33Z	Introduction of Anti-inflammatory into Lymphatics, Percutaneous Approach
3E0W3GC	Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach
3E0W3TZ	Introduction of Destructive Agent into Lymphatics, Percutaneous Approach
3E0X33Z	Introduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach
3E0Y33Z	Introduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach
XW03331	Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1

XW04331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1

XW04351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1

NDC	Product	Titles	Form	thercls	
00002145201	VELBAN	VINBLASTINE SULFATE	Powder for	Antineoplastic NEC	Agents,
00002719401	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719501	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719601	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719801	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719809	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719901	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002719909	ONCOVIN	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00002750101	GEMZAR	GEMCITABINE HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00002750201	GEMZAR	GEMCITABINE HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00002762301	ALIMTA	Pemetrexed	Powder for	Antineoplastic NEC	Agents,
00002764001	ALIMTA	Pemetrexed	Powder for	Antineoplastic NEC	Agents,
00003052411	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
00003052711	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
00003052811	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
00003069050	TESLAC	TESTOLACTONE	Tablet	Antineoplastic NEC	Agents,
00003085222	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
00004005301	MATULANE	PROCARBAZINE HYDROCHLORIDE	Capsule	Antineoplastic NEC	Agents,

00004025001	VESANOID	TRETINOIN	Capsule,	Antineoplastic NEC	Agents,
00004110020	XELODA	CAPECITABINE	Tablet	Antineoplastic NEC	Agents,
00004110051	XELODA	CAPECITABINE	Tablet	Antineoplastic NEC	Agents,
00004110116	XELODA	CAPECITABINE	Tablet	Antineoplastic NEC	Agents,
00004110150	XELODA	CAPECITABINE	Tablet	Antineoplastic NEC	Agents,
00004150603	EFUDEX	FLUOROURACIL	Cream	Antineoplastic NEC	Agents,
00004170406	EFUDEX	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00004170506	EFUDEX	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00004190406	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic NEC	Agents,
00004193508	FUDR	FLOXURIDINE	Powder for	Antineoplastic NEC	Agents,
00004197701	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic NEC	Agents,
00006056840	ZOLINZA	Vorinostat	Capsule	Antineoplastic NEC	Agents,
00006329822	COSMEGEN	DACTINOMYCIN	Powder for	Antineoplastic NEC	Agents,
00006461200	ELSPAR	ASPARAGINASE	Powder for	Antineoplastic NEC	Agents,
00006775331	MUSTARGEN	MECHLORETHAMINE	Powder for	Antineoplastic NEC	Agents,
00007326031	BEXXAR	Tositumomab	Solution	Antineoplastic NEC	Agents,
00007326036	BEXXAR	Tositumomab	Solution	Antineoplastic NEC	Agents,
00007326101	BEXXAR	Iodine I 131 Tositumomab	Solution	Antineoplastic NEC	Agents,
00007326201	BEXXAR	Iodine I 131 Tositumomab	Solution	Antineoplastic NEC	Agents,
00007420101	HYCAMTIN	TOPOTECAN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00007420105	HYCAMTIN	TOPOTECAN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00007420511	HYCAMTIN	TOPOTECAN HYDROCHLORIDE	Capsule	Antineoplastic NEC	Agents,

00007420711	HYCAMTIN	TOPOTECAN HYDROCHLORIDE	Capsule	Antineoplastic NEC	Agents,
00007440101	ARRANON	Nelarabine	Solution	Antineoplastic NEC	Agents,
00007440106	ARRANON	Nelarabine	Solution	Antineoplastic NEC	Agents,
00008117901	TORISEL	Temsirolimus	Solution	Antineoplastic NEC	Agents,
00008415501	CERUBIDINE	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00008451001	MYLOTARG	GEMTUZUMAB OZOGAMICIN	Powder for	Antineoplastic NEC	Agents,
00009037301	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009047301	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009084401	ZANOSAR	STREPTOZOCIN	Powder for	Antineoplastic NEC	Agents,
00009094901	URACIL	URACIL MUSTARD	Capsule	Antineoplastic NEC	Agents,
00009306301	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009307001	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009329501	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009329601	CYTOSAR-U	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
00009509101	ELLENCE	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009509301	ELLENCE	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009521501	TRELSTAR LA	TRIPTORELIN PAMOATE	Powder for	Antineoplastic NEC	Agents,
00009521601	TRELSTAR LA	TRIPTORELIN PAMOATE	Suspension	Antineoplastic NEC	Agents,
00009521901	TRELSTAR DEPOT	TRIPTORELIN PAMOATE	Powder for	Antineoplastic NEC	Agents,
00009752901	CAMPTOSAR	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009752902	CAMPTOSAR	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009766304	AROMASIN	EXEMESTANE	Tablet	Antineoplastic NEC	Agents,

00009766401	TRELSTAR DEPOT	TRIPTORELIN PAMOATE	Powder for	Antineoplastic NEC	Agents,
00013013202	EMCYT	ESTRAMUSTINE PHOSPHATE	Capsule	Antineoplastic NEC	Agents,
00013100691	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013101679	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013102691	ADRUCIL	FLUOROURACIL	Injectable	Antineoplastic NEC	Agents,
00013103691	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00013104694	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00013105694	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00013107694	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013108691	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013109691	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013109694	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013110679	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013111683	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013113691	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013114691	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013114694	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic NEC	Agents,
00013115679	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013116683	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013117687	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013123691	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013124691	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,

00013125679	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013126683	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013128683	ADRIAMYCIN PFS	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013161678	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic NEC	Agents,
00013163686	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic NEC	Agents,
00013220001	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013220101	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013220201	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013250694	IDAMYCIN	IDARUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013251686	IDAMYCIN	IDARUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013252686	IDAMYCIN	IDARUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00013253678	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013254686	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013255667	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013257691	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013258691	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013259691	IDAMYCIN PFS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00013560693	NEOSAR	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00013561693	NEOSAR	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00013562693	NEOSAR	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00013563670	NEOSAR	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00013564670	NEOSAR	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,

00013709173	TARABINE PFS	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00013710678	TARABINE PFS	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00013733691	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00013734694	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00013735688	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00013737686	VELSAR	VINBLASTINE SULFATE	Powder for	Antineoplastic NEC	Agents,
00013744686	VINCASAR PFS	VINCRISTINE SULFATE	Injectable	Antineoplastic NEC	Agents,
00013745686	VINCASAR PFS	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00013746686	VINCASAR PFS	VINCRISTINE SULFATE	Solution	Antineoplastic NEC	Agents,
00015050041	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015050141	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015050241	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015050301	CYTOXAN	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic NEC	Agents,
00015050302	CYTOXAN	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic NEC	Agents,
00015050303	CYTOXAN	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic NEC	Agents,
00015050348	CYTOXAN	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic NEC	Agents,
00015050401	CYTOXAN	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic NEC	Agents,
00015050541	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015050641	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015053941	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015054641	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,
00015054712	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic NEC	Agents,

00015054741	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic	Agents, NEC
00015054812	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic	Agents, NEC
00015054841	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic	Agents, NEC
00015054912	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic	Agents, NEC
00015054941	CYTOXAN	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic	Agents, NEC
00015055605	IFEX	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
00015055611	IFEX NOVAPLUS	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
00015055641	IFEX	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
00015055711	IFEX NOVAPLUS	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
00015055741	IFEX	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
00015191012	IXEMPRA	Ixabepilone	Powder for	Antineoplastic	Agents, NEC
00015191113	IXEMPRA	Ixabepilone	Powder for	Antineoplastic	Agents, NEC
00015300120	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic	Agents, NEC
00015300197	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic	Agents, NEC
00015300220	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic	Agents, NEC
00015300222	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic	Agents, NEC
00015301020	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00015301026	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00015301097	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00015301238	BICNU	CARMUSTINE	Powder for	Antineoplastic	Agents, NEC
00015301260	BICNU	CARMUSTINE	Powder for	Antineoplastic	Agents, NEC
00015301297	BICNU	CARMUSTINE	Powder for	Antineoplastic	Agents, NEC

00015303020	CEENU	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
00015303120	CEENU	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
00015303220	CEENU	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
00015303410	CEENU	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
00015305920	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
00015306120	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015306124	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015306220	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015306224	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015306301	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic NEC	Agents,
00015306326	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic NEC	Agents,
00015307020	PLATINOL	CISPLATIN	Powder for	Antineoplastic NEC	Agents,
00015307097	PLATINOL	CISPLATIN	Powder for	Antineoplastic NEC	Agents,
00015307220	PLATINOL	CISPLATIN	Powder for	Antineoplastic NEC	Agents,
00015307297	PLATINOL	CISPLATIN	Powder for	Antineoplastic NEC	Agents,
00015307519	VUMON	TENIPOSIDE	Solution	Antineoplastic NEC	Agents,
00015307597	VUMON	TENIPOSIDE	Solution	Antineoplastic NEC	Agents,
00015308060	LYSODREN	MITOTANE	Tablet	Antineoplastic NEC	Agents,
00015308420	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015309145	VEPESID	ETOPOSIDE	Capsule,	Antineoplastic NEC	Agents,
00015309520	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00015309530	VEPESID	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,

00015321030	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321076	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321130	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321176	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321230	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321276	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015321329	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321330	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321429	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321430	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321529	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321530	PARAPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00015321630	PARAPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015322022	PLATINOL-AQ	CISPLATIN	Solution	Antineoplastic Agents, NEC
00015322026	PLATINOL-AQ	CISPLATIN	Solution	Antineoplastic Agents, NEC
00015322122	PLATINOL-AQ	CISPLATIN	Solution	Antineoplastic Agents, NEC
00015322126	PLATINOL-AQ	CISPLATIN	Solution	Antineoplastic Agents, NEC
00015323011	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015323111	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015323211	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015323311	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00015335122	RUBEX	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC

00015335222	RUBEX	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC
00015335322	RUBEX	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC
00015340420	ETOPOPHOS	ETOPOSIDE PHOSPHATE	Powder for	Antineoplastic Agents, NEC
00015345699	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015347520	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015347530	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015347620	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015347630	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015347911	TAXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00015355410	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355427	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355610	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355626	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355741	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355841	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015355941	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015356410	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00015356415	IFEX/MESNEX	IFOSFAMIDE/MESNA	Kit	Antineoplastic Agents, NEC
00019N461F0	SODIUM	Sodium Phosphate P 32	Solution	Antineoplastic Agents, NEC
00019N470P0	PHOSPHOCOL P-	Chromic Phosphate P 32	Suspension	Antineoplastic Agents, NEC
00024022205	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024059010	ELOXATIN	OXALIPLATIN	Solution	Antineoplastic Agents, NEC

00024059120	ELOXATIN	OXALIPLATIN	Solution	Antineoplastic Agents, NEC
00024059240	ELOXATIN	OXALIPLATIN	Solution	Antineoplastic Agents, NEC
00024059602	ELOXATIN	OXALIPLATIN	Powder for	Antineoplastic Agents, NEC
00024059704	ELOXATIN	OXALIPLATIN	Powder for	Antineoplastic Agents, NEC
00024059707	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024059722	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024060545	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024061030	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024079375	ELIGARD	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00024155001	PHOTOFRIN	PORFIMER SODIUM	Powder for	Antineoplastic Agents, NEC
00024582005	OFORTA	FLUDARABINE PHOSPHATE	Tablet	Antineoplastic Agents, NEC
00024582020	OFORTA	FLUDARABINE PHOSPHATE	Tablet	Antineoplastic Agents, NEC
00026815110	DTIC-DOME	DACARBAZINE	Powder for	Antineoplastic Agents, NEC
00026815120	DTIC-DOME	DACARBAZINE	Powder for	Antineoplastic Agents, NEC
00026816115	MITHRACIN	PLICAMYCIN	Powder for	Antineoplastic Agents, NEC
00026848858	NEXAVAR	Sorafenib Tosylate	Tablet	Antineoplastic Agents, NEC
00026971101	VIADUR	LEUPROLIDE ACETATE	Kit	Antineoplastic Agents, NEC
00054412925	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
00054413025	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
00054458111	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic Agents, NEC
00054458127	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic Agents, NEC
00054483121	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC

00054483126	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00054483413	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00054483422	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00054808925	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
00054813025	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
00054883125	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00054883425	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00069055030	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00069055038	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00069077030	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00069077038	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00069098030	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00069098038	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
00074148501	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC
00074148502	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC
00074148503	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC
00074210803	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074228203	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074244003	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074334603	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074364103	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074364203	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC

00074366303	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074368303	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
00074433501	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00074433502	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00074433504	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00074736301	VERCYTE	PIPOBROMAN	Tablet	Antineoplastic Agents, NEC
00075064005	ONCASPAR	PEGASPARGASE	Solution	Antineoplastic Agents, NEC
00075800120	TAXOTERE	DOCETAXEL	Solution	Antineoplastic Agents, NEC
00075800180	TAXOTERE	DOCETAXEL	Solution	Antineoplastic Agents, NEC
00075999508	GLIADEL	CARMUSTINE	Implant	Antineoplastic Agents, NEC
00078024915	FEMARA	LETROZOLE	Tablet	Antineoplastic Agents, NEC
00078037366	GLEEVEC	IMATINIB MESYLATE	Capsule	Antineoplastic Agents, NEC
00078040105	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC
00078040134	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC
00078040215	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC
00078043815	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC
00078049561	PROLEUKIN	ALDESLEUKIN	Powder for	Antineoplastic Agents, NEC
00078052651	TASIGNA	Nilotinib Hydrochloride	Capsule	Antineoplastic Agents, NEC
00078052687	TASIGNA	Nilotinib Hydrochloride	Capsule	Antineoplastic Agents, NEC
00078056651	AFINITOR	Everolimus	Tablet	Antineoplastic Agents, NEC
00078056661	AFINITOR	Everolimus	Tablet	Antineoplastic Agents, NEC
00078056751	AFINITOR	Everolimus	Tablet	Antineoplastic Agents, NEC

00078056761	AFINITOR	Everolimus	Tablet	Antineoplastic Agents, NEC	
00081039001	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic Agents, NEC	
00081039003	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic Agents, NEC	
00085052503	EULEXIN	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00085052504	EULEXIN	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00085052505	EULEXIN	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00085052506	EULEXIN	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00085112601	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic Agents, NEC	
00085112602	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic Agents, NEC	
00085124401	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085124402	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085124801	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085124802	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085124803	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085125201	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085125202	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085125901	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085125902	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085136601	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085136602	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085138101	TEMODAR	TEMOZOLOMIDE	Powder for	Antineoplastic Agents, NEC	
00085141701	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	

00085142501	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085142502	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085143001	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085143002	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085151901	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085151902	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085300401	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085300402	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00088111035	NILANDRON	NILUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00088111114	NILANDRON	NILUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00093022001	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00093022056	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00093078201	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078205	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078210	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078256	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078405	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078406	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078410	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093078486	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00093551006	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic Agents, NEC	
00093712005	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	

00093712086	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00094534101	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
00094534201	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
00094534501	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
00172375377	ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375396	NOV-ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375473	ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375494	NOV-ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375531	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375675	ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172375695	NOV-ONXOL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00172496058	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00172496070	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00172565649	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565658	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565670	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565680	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565746	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565760	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565770	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00172565780	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00173004535	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC	

00173013093	ALKERAN	Melphalan Hydrochloride	Powder for	Antineoplastic Agents, NEC	
00173063535	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC	
00173065601	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00173065644	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00173071325	MYLERAN	BUSULFAN	Tablet	Antineoplastic Agents, NEC	
00173075200	TYKERB	Lapatinib Ditosylate	Tablet	Antineoplastic Agents, NEC	
00173080409	VOTRIENT	Pazopanib Hydrochloride	Tablet	Antineoplastic Agents, NEC	
00173080725	PURINETHOL	MERCAPTOPURINE	Tablet	Antineoplastic Agents, NEC	
00173080765	PURINETHOL	MERCAPTOPURINE	Tablet	Antineoplastic Agents, NEC	
00173080802	ARZERRA	Ofatumumab	Solution	Antineoplastic Agents, NEC	
00173080805	ARZERRA	Ofatumumab	Solution	Antineoplastic Agents, NEC	
00173088025	THIOGUANINE	THIOGUANINE	Tablet	Antineoplastic Agents, NEC	
00182306863	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic Agents, NEC	
00182315499	LEUPROLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic Agents, NEC	
00185112505	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00185112518	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00185112588	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00185740014	LEUPROLIDE	LEUPROLIDE ACETATE	Solution	Antineoplastic Agents, NEC	
00185740085	LEUPROLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic Agents, NEC	
00186153013	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
00186153101	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
00186153231	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

00186153241	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00186153261	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00186153281	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00186157131	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00186157512	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
00187395364	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
00209306022	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00209307020	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00209308020	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00209309020	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00300210601	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300210801	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300228201	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300243701	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300244001	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300333601	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300334301	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300334601	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic NEC	Agents,
00300361224	LUPRON	LEUPROLIDE ACETATE	Kit	Antineoplastic NEC	Agents,
00300361228	LUPRON	LEUPROLIDE ACETATE	Kit	Antineoplastic NEC	Agents,
00300362624	LUPRON	LEUPROLIDE ACETATE	Solution	Antineoplastic NEC	Agents,
00300362628	LUPRON	LEUPROLIDE ACETATE	Kit	Antineoplastic NEC	Agents,

00300362630	LUPRON	LEUPROLIDE ACETATE	Kit	Antineoplastic	Agents, NEC
00300362901	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300362906	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300363901	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300363906	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300364101	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300364201	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300366301	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300367301	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300368301	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00300368906	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
00310020130	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic	Agents, NEC
00310020137	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic	Agents, NEC
00310048230	IRESSA	Gefitinib	Tablet	Antineoplastic	Agents, NEC
00310060018	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060025	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060060	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060075	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060412	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060430	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310060490	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00310070510	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic	Agents, NEC

00310070530	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00310070539	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00310072025	FASLODEX	FULVESTRANT	Solution	Antineoplastic Agents, NEC	
00310072050	FASLODEX	FULVESTRANT	Solution	Antineoplastic Agents, NEC	
00310073060	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00310073130	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00310095036	ZOLADEX	GOSERELIN ACETATE	Implant	Antineoplastic Agents, NEC	
00310095130	ZOLADEX	GOSERELIN ACETATE	Implant	Antineoplastic Agents, NEC	
00310096036	ZOLADEX	GOSERELIN ACETATE	Implant	Antineoplastic Agents, NEC	
00310096130	ZOLADEX	GOSERELIN ACETATE	Implant	Antineoplastic Agents, NEC	
00338399101	IFEX	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC	
00338399301	IFEX	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC	
00364244754	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic Agents, NEC	
00364244851	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00364244852	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00364246753	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00364246854	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00364302853	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00378014405	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00378014491	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00378027401	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00378027493	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	

00378326694	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic	Agents, NEC
00378354725	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
00378354752	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
00378701705	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic	Agents, NEC
00378701793	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic	Agents, NEC
00402102710	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic	Agents, NEC
00402102801	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic	Agents, NEC
00402102802	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic	Agents, NEC
00403059118	MUTAMYCIN	MITOMYCIN	Powder for	Antineoplastic	Agents, NEC
00403150571	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
00403483518	THIOPLEX	THIOTEPA	Powder for	Antineoplastic	Agents, NEC
00409080101	NIPENT	PENTOSTATIN	Powder for	Antineoplastic	Agents, NEC
00409112910	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00409112911	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00409112912	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00418880210	BCG THERACYS	Bacillus of Calmette and Guerin	Powder for	Antineoplastic	Agents, NEC
00469100161	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic	Agents, NEC
00469163000	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
00469163010	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
00469163030	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
00469171030	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
00469171040	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC

00469171060	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
00469171100	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
00469227030	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
00469228040	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
00469278030	VINBLASTINE	VINBLASTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
00469352000	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00469352010	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00469352020	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00469883020	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic Agents, NEC	
00469883130	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic Agents, NEC	
00469883250	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic Agents, NEC	
00555044603	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555044605	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555044609	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555044663	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555080802	TRETINOIN	TRETINOIN	Capsule,	Antineoplastic Agents, NEC	
00555087004	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00555087063	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC	
00555090401	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555090405	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555090414	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
00555198414	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	

00555198514	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
00591221911	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00591222011	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00591222718	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC
00591223218	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00591223260	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00591223319	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00591223330	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
00591318902	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00591318926	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00591333626	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00591333712	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00591333889	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00591345460	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
00591346983	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00591347057	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00591368711	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
00641226241	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
00641226341	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
00641226441	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
00641226541	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
00702023110	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC

00702023206	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
00702023301	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
00702023510	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
00702023606	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
00702023701	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
00702171030	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
00703301513	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
00703301812	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
00703301912	ADRUCIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
00703306711	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703306911	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703315401	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00703315491	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00703315501	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00703315591	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
00703324411	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00703324611	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00703324811	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00703324911	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
00703326401	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703326601	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703326801	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC

00703326871	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703327401	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703327601	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703327801	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
00703342711	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic	Agents, NEC
00703342911	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic	Agents, NEC
00703398501	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic	Agents, NEC
00703398601	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic	Agents, NEC
00703401418	LEUPROLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic	Agents, NEC
00703401419	LEUPROLIDE	LEUPROLIDE ACETATE	Solution	Antineoplastic	Agents, NEC
00703410048	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703410058	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703410068	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703410948	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703410958	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703410968	IFOSFAMIDE/ME	IFOSFAMIDE/MESNA	Kit	Antineoplastic	Agents, NEC
00703415411	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703415491	NOVAPLUS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703415511	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703415591	NOVAPLUS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703415611	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
00703415691	NOVAPLUS	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC

00703418201	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703418281	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703418291	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703418301	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703418381	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703418391	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
00703424401	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
00703424601	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
00703424801	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
00703430102	THIOTEPA	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
00703430301	THIOTEPA	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
00703440211	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00703441211	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
00703443211	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703443411	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703443491	NOVAPLUS	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703443711	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703463601	ZANOSAR	STREPTOZOCIN	Powder for	Antineoplastic Agents, NEC	
00703465801	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
00703468001	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
00703468091	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
00703468501	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	

00703468591	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
00703468601	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
00703468691	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
00703476401	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00703476601	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00703476701	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00703476801	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
00703485211	FLUDARABINE	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
00703485281	OTN	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
00703485292	NOVAPLUS	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
00703503001	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
00703503203	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
00703504001	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703504303	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703504601	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00703507501	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
00703507503	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
00703518203	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00703519302	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00703519401	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00703519501	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
00703523313	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

00703564301	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703564601	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703565301	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703565601	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703565701	TOPOSAR	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703566701	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703566801	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
00703574711	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
00703574811	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
00703585401	FLUDARABINE	FLUDARABINE PHOSPHATE	Powder for	Antineoplastic Agents, NEC	
00781306672	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00781306675	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
00781540901	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00781540931	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00781540964	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00904601946	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
00904601960	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
10019091001	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
10019091002	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
10019091201	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
10019091202	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
10019091203	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	

10019091501	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
10019091601	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
10019091701	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC
10019092001	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC
10019092102	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC
10019092501	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC
10019092582	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC
10019092602	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC
10019092616	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic Agents, NEC
10019093001	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC
10019093002	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC
10019093401	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10019093402	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10019093417	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10019093479	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10019095002	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10019095501	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
10019095550	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
10019095601	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
10019095616	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
10019095701	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC
10019095711	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Powder for	Antineoplastic Agents, NEC

10019097001	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
10019097002	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
10139006005	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
10139006015	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
10139006045	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC
10139006101	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10139006125	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10139006301	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10139006310	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10139006311	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10139006312	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10139006320	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10139006350	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC
10518010207	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
10518010208	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
10518010209	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC
10518010310	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10518010311	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10518010410	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10518010411	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
10518010510	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC
10518010511	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC

10518010512	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
11399000501	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic Agents, NEC	
11399000530	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic Agents, NEC	
11793088001	THERACYS	Bacillus of Calmette and Guerin	Powder for	Antineoplastic Agents, NEC	
11793880201	THERACYS	Bacillus of Calmette and Guerin	Powder for	Antineoplastic Agents, NEC	
12280034630	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic Agents, NEC	
13632012301	SOLTAMOX	TAMOXIFEN CITRATE	Solution	Antineoplastic Agents, NEC	
15210006112	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
15210006312	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
15210006612	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
15210006712	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
15210040335	OTN	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
15210040336	OTN	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
15210040337	OTN	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
16714057101	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
16714057102	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
16729002301	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
16729002310	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
16729010811	MITOMYCIM	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
16729011505	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
17314960001	DOXIL	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
17314960002	DOXIL	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

18111000202	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
18111000203	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021020002	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021020005	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021020325	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021020351	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021020505	FLUDARABINE	FLUDARABINE PHOSPHATE	Powder for	Antineoplastic NEC	Agents,
35356027030	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic NEC	Agents,
35356040930	FEMARA	LETROZOLE	Tablet	Antineoplastic NEC	Agents,
39769001210	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
39769001240	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
39769001250	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic NEC	Agents,
39769001290	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
41616017840	OXALIPLATIN	OXALIPLATIN	Powder for	Antineoplastic NEC	Agents,
41616048583	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
41616048588	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
41616093640	LEUPROLIDE	LEUPROLIDE ACETATE	Solution	Antineoplastic NEC	Agents,
44087152001	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic NEC	Agents,
44087152501	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic NEC	Agents,
44087153001	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic NEC	Agents,
48818000101	FOLOTYN	Pralatrexate	Solution	Antineoplastic NEC	Agents,
48818000102	FOLOTYN	Pralatrexate	Solution	Antineoplastic NEC	Agents,

49281088001	THERACYS	Bacillus of Calmette and Guerin	Powder for	Antineoplastic	Agents, NEC
49884036826	LEUPROLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic	Agents, NEC
49884075305	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic	Agents, NEC
49884075313	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic	Agents, NEC
49884092202	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
49884092204	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
49999098630	AROMASIN	EXEMESTANE	Tablet	Antineoplastic	Agents, NEC
50111096576	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
50111096676	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
50111096776	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
50242005121	RITUXAN	RITUXIMAB	Solution	Antineoplastic	Agents, NEC
50242005306	RITUXAN	RITUXIMAB	Solution	Antineoplastic	Agents, NEC
50242005656	HERCEPTIN	TRASTUZUMAB	Powder for	Antineoplastic	Agents, NEC
50242006001	AVASTIN	Bevacizumab	Solution	Antineoplastic	Agents, NEC
50242006002	AVASTIN	Bevacizumab	Solution	Antineoplastic	Agents, NEC
50242006101	AVASTIN	Bevacizumab	Solution	Antineoplastic	Agents, NEC
50242006201	TARCEVA	Erlotinib	Tablet	Antineoplastic	Agents, NEC
50242006301	TARCEVA	Erlotinib	Tablet	Antineoplastic	Agents, NEC
50242006401	TARCEVA	Erlotinib	Tablet	Antineoplastic	Agents, NEC
50242013460	HERCEPTIN	TRASTUZUMAB	Powder for	Antineoplastic	Agents, NEC
50242013468	HERCEPTIN	TRASTUZUMAB	Powder for	Antineoplastic	Agents, NEC
50419035510	CAMPATH	ALEMTUZUMAB	Solution	Antineoplastic	Agents, NEC

50419035512	CAMPATH	ALEMTUZUMAB	Solution	Antineoplastic Agents, NEC	
50419035703	CAMPATH	ALEMTUZUMAB	Solution	Antineoplastic Agents, NEC	
50419048858	NEXAVAR	Sorafenib Tosylate	Tablet	Antineoplastic Agents, NEC	
50419051106	FLUDARA	FLUDARABINE PHOSPHATE	Powder for	Antineoplastic Agents, NEC	
50458027036	ERGAMISOL	LEVAMISOLE HYDROCHLORIDE	Tablet	Antineoplastic Agents, NEC	
51079069201	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
51079069203	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
51079096101	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
51079096201	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
51079096301	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
51079096505	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic Agents, NEC	
51309020002	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
51309020003	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
51309020005	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
51309020102	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
51309020105	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic Agents, NEC	
51309020220	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51309020230	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51309020320	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic Agents, NEC	
51309020410	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
51309020420	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
51309020520	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	

51309020530	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
51309021720	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
51309021750	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
51309021798	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
51309021910	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
51309022015	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
51309022205	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
51309022330	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
51309023110	FLOXURIDINE	FLOXURIDINE	Powder for	Antineoplastic Agents, NEC	
51309023210	FLOXURIDINE	FLOXURIDINE	Injectable	Antineoplastic Agents, NEC	
51309025450	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
51432040910	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
51432041910	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51432047010	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
51432047505	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51432047601	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51432047702	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
51432047810	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
52152052602	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
52152052630	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
52544015302	TRELSTAR DEPOT	TRIPTORELIN PAMOATE	Powder for	Antineoplastic Agents, NEC	
52544015376	TRELSTAR DEPOT	TRIPTORELIN PAMOATE	Powder for	Antineoplastic Agents, NEC	

52544015402	TRELSTAR LA	TRIPTORELIN PAMOATE	Powder for	Antineoplastic	Agents, NEC
52544015476	TRELSTAR LA	TRIPTORELIN PAMOATE	Powder for	Antineoplastic	Agents, NEC
52544018876	TRELSTAR LA	TRIPTORELIN PAMOATE	Powder for	Antineoplastic	Agents, NEC
52544018976	TRELSTAR DEPOT	TRIPTORELIN PAMOATE	Powder for	Antineoplastic	Agents, NEC
53014021604	VALSTAR	VALRUBICIN	Solution	Antineoplastic	Agents, NEC
53014021624	VALSTAR	VALRUBICIN	Solution	Antineoplastic	Agents, NEC
53258035200	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53258035201	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53258035202	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53258162003	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic	Agents, NEC
53258171003	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic	Agents, NEC
53258171100	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic	Agents, NEC
53258227003	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic	Agents, NEC
53258228004	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic	Agents, NEC
53443000207	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic	Agents, NEC
53443000740	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53443000741	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53443000743	VINCRISTINE	VINCRISTINE SULFATE	Injectable	Antineoplastic	Agents, NEC
53905011110	FLUOROURACIL	FLUOROURACIL	Injectable	Antineoplastic	Agents, NEC
53905023206	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
53905023606	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
53905033101	DEPOCYT	CYTARABINE LIPOSOME	Suspension	Antineoplastic	Agents, NEC

53905099101	PROLEUKIN	ALDESLEUKIN	Powder for	Antineoplastic	Agents, NEC
53905099110	PROLEUKIN	ALDESLEUKIN	Powder for	Antineoplastic	Agents, NEC
54092003950	URACIL	URACIL MUSTARD	Capsule	Antineoplastic	Agents, NEC
54092017001	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic	Agents, NEC
54092017030	FARESTON	TOREMIFENE CITRATE	Tablet	Antineoplastic	Agents, NEC
54482005301	MATULANE	PROCARBAZINE HYDROCHLORIDE	Capsule	Antineoplastic	Agents, NEC
54569038200	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
54569038202	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
54569110000	EFUDEX	FLUOROURACIL	Cream	Antineoplastic	Agents, NEC
54569140600	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic	Agents, NEC
54569271300	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
54569296200	CYTARABINE	CYTARABINE	Powder for	Antineoplastic	Agents, NEC
54569344400	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
54569376500	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
54569376501	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
54569394200	EULEXIN	FLUTAMIDE	Capsule	Antineoplastic	Agents, NEC
54569394300	ZOLADEX	GOSERELIN ACETATE	Implant	Antineoplastic	Agents, NEC
54569415200	ELSPAR	ASPARAGINASE	Powder for	Antineoplastic	Agents, NEC
54569415400	IDAMYCIN	IDARUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
54569415500	IDAMYCIN	IDARUBICIN HYDROCHLORIDE	Powder for	Antineoplastic	Agents, NEC
54569452600	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC
54569454700	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic	Agents, NEC

54569478500	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
54569498200	LUPRON	LEUPROLIDE ACETATE	Kit	Antineoplastic Agents, NEC
54569526200	LUPRON DEPOT-	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
54569571200	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54569571300	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54569571400	FEMARA	LETROZOLE	Tablet	Antineoplastic Agents, NEC
54569571600	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54569571700	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54569571800	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic Agents, NEC
54569573100	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic Agents, NEC
54569573200	AROMASIN	EXEMESTANE	Tablet	Antineoplastic Agents, NEC
54569575100	EMCYT	ESTRAMUSTINE PHOSPHATE	Capsule	Antineoplastic Agents, NEC
54569583600	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569583700	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569583800	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569583900	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569584200	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569584300	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569584400	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569584500	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54569584600	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC
54569584700	TARCEVA	Erlotinib	Tablet	Antineoplastic Agents, NEC

54569584800	TARCEVA	Erlotinib	Tablet	Antineoplastic Agents, NEC
54569585700	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54569585900	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC
54569598200	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
54569598300	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC
54569613600	LEUPROLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic Agents, NEC
54569853100	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54569860200	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868112600	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868112601	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868112602	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868112603	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868112604	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868112605	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic Agents, NEC
54868136600	MATULANE	PROCARBAZINE HYDROCHLORIDE	Capsule	Antineoplastic Agents, NEC
54868282500	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
54868300401	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868300402	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868300403	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868300404	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868300405	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868313100	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC

54868318300	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC
54868319600	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC
54868327700	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC
54868329800	BLENOXANE	BLEOMYCIN SULFATE	Powder for	Antineoplastic Agents, NEC
54868414200	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414201	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414202	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414203	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414204	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414205	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414206	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
54868414300	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868414301	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868414302	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868414303	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868415100	FEMARA	LETROZOLE	Tablet	Antineoplastic Agents, NEC
54868428700	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868428701	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868428702	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868428703	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868428704	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC
54868433900	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC

54868433901	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC
54868433902	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC
54868433903	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC
54868433904	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC
54868450300	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC
54868462800	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic Agents, NEC
54868500000	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic Agents, NEC
54868500500	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54868500501	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54868521800	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54868521801	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54868521802	CYCLOPHOSPHA	CYCLOPHOSPHAMIDE	Tablet	Antineoplastic Agents, NEC
54868526000	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526001	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526002	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526003	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526004	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526005	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526006	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526007	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526008	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC
54868526009	XELODA	CAPECITABINE	Tablet	Antineoplastic Agents, NEC

54868526100	AROMASIN	EXEMESTANE	Tablet	Antineoplastic	Agents, NEC
54868528200	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
54868528201	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic	Agents, NEC
54868528900	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868528901	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868528902	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868528903	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868528904	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868529000	TARCEVA	Erlotinib	Tablet	Antineoplastic	Agents, NEC
54868534800	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868534801	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535000	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535001	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535002	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535003	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535004	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535400	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic	Agents, NEC
54868535500	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic	Agents, NEC
54868535501	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic	Agents, NEC
54868535502	ETOPOSIDE	ETOPOSIDE	Capsule,	Antineoplastic	Agents, NEC
54868542700	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC
54868542701	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic	Agents, NEC

54868542702	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic Agents, NEC	
54868544700	TARCEVA	Erlotinib	Tablet	Antineoplastic Agents, NEC	
54868547400	TARCEVA	Erlotinib	Tablet	Antineoplastic Agents, NEC	
54868556800	LUPRON DEPOT	LEUPROLIDE ACETATE	Powder for	Antineoplastic Agents, NEC	
54868557300	SUTENT	Sunitinib Malate	Capsule	Antineoplastic Agents, NEC	
54868559600	PROLEUKIN	ALDESLEUKIN	Powder for	Antineoplastic Agents, NEC	
54868573400	NILANDRON	NILUTAMIDE	Tablet	Antineoplastic Agents, NEC	
54868575900	SPRYCEL	Dasatinib	Tablet	Antineoplastic Agents, NEC	
54868598000	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
55175550006	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
55175550503	ARIMIDEX	ANASTROZOLE	Tablet	Antineoplastic Agents, NEC	
55289058530	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
55390000501	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic Agents, NEC	
55390000601	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic Agents, NEC	
55390003010	THIOTEPA	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
55390006901	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
55390007001	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
55390008301	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
55390008401	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
55390008501	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
55390009010	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
55390009110	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic Agents, NEC	

55390009901	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
55390010801	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390010810	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390011250	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
55390011299	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
55390011405	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390011420	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390011450	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390011501	CLADRIBINE	CLADRIBINE	Solution	Antineoplastic Agents, NEC	
55390012401	CLADRIBINE	CLADRIBINE	Solution	Antineoplastic Agents, NEC	
55390013110	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
55390013210	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
55390013301	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
55390013401	CYTARABINE	CYTARABINE	Powder for	Antineoplastic Agents, NEC	
55390013501	FLOXURIDINE	FLOXURIDINE	Powder for	Antineoplastic Agents, NEC	
55390014210	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390015001	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC	
55390015101	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC	
55390015201	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic Agents, NEC	
55390015301	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390015401	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390015501	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	

55390015601	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390018701	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
55390020701	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390020801	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390021501	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390021601	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390021701	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390022001	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390022101	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390022201	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
55390023110	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390023210	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390023301	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390023510	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390023610	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390023701	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390023801	ADRIAMYCIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390024110	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390024210	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390024301	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390024401	PENTOSTATIN	PENTOSTATIN	Powder for	Antineoplastic Agents, NEC	
55390024510	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

55390024610	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390024701	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390024801	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390025101	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
55390025201	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
55390025301	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
55390026701	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
55390026801	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
55390028110	CERUBIDINE	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
55390029101	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
55390029201	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
55390029301	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
55390029501	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390029601	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
55390030405	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390030420	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390030450	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390031405	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390031420	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390031450	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
55390033910	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
55390041450	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	

55390041499	CISPLATIN	CISPLATIN	Solution	Antineoplastic NEC	Agents,
55390043501	FLOXURIDINE	FLOXURIDINE	Powder for	Antineoplastic NEC	Agents,
55390045101	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
55390045201	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
55390045301	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
55390049101	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
55390049201	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
55390049301	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
55390051405	PACLITAXEL OTN	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
55390051420	PACLITAXEL OTN	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
55390051450	PACLITAXEL OTN	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
55390051505	LEUPROLIDE	LEUPROLIDE ACETATE	Solution	Antineoplastic NEC	Agents,
55390080510	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic NEC	Agents,
55390080610	CYTARABINE	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
55390080710	CYTARABINE	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
55390080801	CYTARABINE	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
55390080901	CYTARABINE	CYTARABINE	Powder for	Antineoplastic NEC	Agents,
55513095401	VECTIBIX	Panitumumab	Solution	Antineoplastic NEC	Agents,
55513095501	VECTIBIX	Panitumumab	Solution	Antineoplastic NEC	Agents,
55513095601	VECTIBIX	Panitumumab	Solution	Antineoplastic NEC	Agents,
55566830100	DEGARELIX	Degarelix Acetate	Powder for	Antineoplastic NEC	Agents,
55566830101	FIRMAGON	Degarelix Acetate	Powder for	Antineoplastic NEC	Agents,

55566840100	DEGARELIX	Degarelix Acetate	Powder for	Antineoplastic NEC	Agents,
55566840101	FIRMAGON	Degarelix Acetate	Powder for	Antineoplastic NEC	Agents,
56146030101	DAUNOXOME	DAUNORUBICIN CITRATE	Solution	Antineoplastic NEC	Agents,
56146030104	DAUNOXOME	DAUNORUBICIN CITRATE	Solution	Antineoplastic NEC	Agents,
57665000202	ONCASPAR	PEGASPARGASE	Solution	Antineoplastic NEC	Agents,
57665033101	DEPOCYT	CYTARABINE LIPOSOME	Suspension	Antineoplastic NEC	Agents,
57844052206	PURINETHOL	MERCAPTOPURINE	Tablet	Antineoplastic NEC	Agents,
57844052207	PURINETHOL	MERCAPTOPURINE	Tablet	Antineoplastic NEC	Agents,
57866661501	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic NEC	Agents,
57866661801	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic NEC	Agents,
57884052207	PURINETHOL	MERCAPTOPURINE	Tablet	Antineoplastic NEC	Agents,
58016017000	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic NEC	Agents,
58016017030	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic NEC	Agents,
58016017060	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic NEC	Agents,
58016017090	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic NEC	Agents,
58016017099	FLUTAMIDE	FLUTAMIDE	Capsule	Antineoplastic NEC	Agents,
58016065760	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic NEC	Agents,
58016201701	EFUDEX	FLUOROURACIL	Cream	Antineoplastic NEC	Agents,
58063000170	HEXALEN	ALTRETAMINE	Capsule	Antineoplastic NEC	Agents,
58063010001	GLIADEL	CARMUSTINE	Implant	Antineoplastic NEC	Agents,
58063060050	DACOGEN	Decitabine	Powder for	Antineoplastic NEC	Agents,
58178000170	HEXALEN	ALTRETAMINE	Capsule	Antineoplastic NEC	Agents,

58406064003	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
58406064005	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
58406064007	NOVANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
58406066102	THIOPLEX	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
58406066131	THIOPLEX	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
58406066201	THIOPLEX	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
58406066236	THIOPLEX	THIOTEPA	Powder for	Antineoplastic Agents, NEC	
58406071112	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
58406071418	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
58468010001	CLOLAR	Clofarabine	Solution	Antineoplastic Agents, NEC	
58468010002	CLOLAR	Clofarabine	Solution	Antineoplastic Agents, NEC	
58914015575	PHOTOFRIN	PORFIMER SODIUM	Powder for	Antineoplastic Agents, NEC	
59148007091	BUSULFEX	BUSULFAN	Solution	Antineoplastic Agents, NEC	
59572010201	VIDAZA	Azacitidine	Powder for	Antineoplastic Agents, NEC	
59572030101	ALKERAN IV	Melphalan Hydrochloride	Powder for	Antineoplastic Agents, NEC	
59572030250	ALKERAN	MELPHALAN	Tablet	Antineoplastic Agents, NEC	
59572040500	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572040528	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572040530	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572041000	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572041028	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572041030	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	

59572041500	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572041521	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572042500	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572042521	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59572042525	REVLIMID	Lenalidomide	Capsule	Antineoplastic Agents, NEC	
59676020101	LEUSTATIN	CLADRIBINE	Solution	Antineoplastic Agents, NEC	
59762257601	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762258601	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762259601	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762509101	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762509301	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762752901	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59762752902	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
59911595801	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
59911595901	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
60346004832	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
60346054881	EFUDEX	FLUOROURACIL	Cream	Antineoplastic Agents, NEC	
60346090060	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
60505264201	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
60505264203	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
60553011110	TRISENOX	ARSENIC TRIOXIDE	Solution	Antineoplastic Agents, NEC	
60831308601	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	

60831308602	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
61379010001	GLIADEL	CARMUSTINE	Implant	Antineoplastic Agents, NEC	
61471029512	DOXIL	DOXORUBICIN HYDROCHLORIDE	Injectable	Antineoplastic Agents, NEC	
61703030346	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030350	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030425	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030436	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030509	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030538	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703030650	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
61703030906	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
61703030916	VINCRISTINE	VINCRISTINE SULFATE	Solution	Antineoplastic Agents, NEC	
61703031018	VINBLASTINE	VINBLASTINE SULFATE	Powder for	Antineoplastic Agents, NEC	
61703031922	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
61703032322	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic Agents, NEC	
61703032722	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
61703033109	FUDR	FLOXURIDINE	Powder for	Antineoplastic Agents, NEC	
61703033218	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic Agents, NEC	
61703033918	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703033922	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703033950	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703033956	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	

61703033961	AMERINET	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703033962	AMERINET	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703033963	AMERINET	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
61703034106	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
61703034109	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
61703034209	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
61703034222	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
61703034250	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
61703034318	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
61703034365	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
61703034366	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic Agents, NEC	
61703034418	FLUDARABINE	FLUDARABINE PHOSPHATE	Powder for	Antineoplastic Agents, NEC	
61703034735	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
61703034859	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
61703034909	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703034916	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703034936	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703034961	AMERINET CHOICE	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703034962	AMERINET CHOICE	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703035901	NOVAPLUS	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
61703035902	NOVAPLUS	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

61703035959	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
61703035991	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
61703035992	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
61703035993	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
61703036018	NOVAPLUS	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
61703036022	NOVAPLUS	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
61703036050	NOVAPLUS	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
61703036318	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
61703036322	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
61703036340	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
61703040932	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
61703040953	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
61703040967	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic NEC	Agents,
61958030101	DAUNOXOME	DAUNORUBICIN CITRATE	Solution	Antineoplastic NEC	Agents,
62161000538	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
62175013232	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
62701001001	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
62701001101	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic NEC	Agents,
62701080001	NIPENT	PENTOSTATIN	Powder for	Antineoplastic NEC	Agents,
62856060001	DACOGEN	Decitabine	Powder for	Antineoplastic NEC	Agents,
62856060210	TARGRETIN	BEXAROTENE	Capsule	Antineoplastic NEC	Agents,

62856060301	ONTAK	DENILEUKIN DIFTITOX	Solution	Antineoplastic Agents, NEC	
63020004901	VELCADE	Bortezomib	Powder for	Antineoplastic Agents, NEC	
63323010161	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323010351	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
63323010364	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
63323010365	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
63323010391	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
63323010395	CISPLATIN	CISPLATIN	Solution	Antineoplastic Agents, NEC	
63323010405	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
63323010425	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
63323010450	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic Agents, NEC	
63323010465	ETOPOSIDE	ETOPOSIDE	Injectable	Antineoplastic Agents, NEC	
63323011710	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
63323011720	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
63323011751	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
63323011761	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
63323011908	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Powder for	Antineoplastic Agents, NEC	
63323012020	CYTARABINE	CYTARABINE	Solution	Antineoplastic Agents, NEC	
63323012404	DAUNORUBICIN	DAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323012710	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	
63323012812	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic Agents, NEC	

63323012820	DACARBAZINE	DACARBAZINE	Powder for	Antineoplastic	Agents, NEC
63323013210	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic	Agents, NEC
63323013212	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic	Agents, NEC
63323013215	MITOXANTRONE	MITOXANTRONE	Solution	Antineoplastic	Agents, NEC
63323013610	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
63323013720	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
63323014010	CLADRIBINE	CLADRIBINE	Solution	Antineoplastic	Agents, NEC
63323014210	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
63323014212	IFOSFAMIDE	IFOSFAMIDE	Powder for	Antineoplastic	Agents, NEC
63323014507	FLOXURIDINE	FLOXURIDINE	Powder for	Antineoplastic	Agents, NEC
63323014801	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
63323014805	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
63323015100	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
63323015105	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
63323015125	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
63323015175	EPIRUBICIN	EPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic	Agents, NEC
63323016610	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
63323016720	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
63323016721	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
63323016800	CARBOPLATIN	CARBOPLATIN	Powder for	Antineoplastic	Agents, NEC
63323017205	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC
63323017215	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic	Agents, NEC

63323017245	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
63323017260	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
63323017530	OXALIPLATIN	OXALIPLATIN	Powder for	Antineoplastic Agents, NEC	
63323017650	OXALIPLATIN	OXALIPLATIN	Powder for	Antineoplastic Agents, NEC	
63323019002	FLUDARABINE	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
63323019020	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
63323019120	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
63323019140	MITOMYCIN	MITOMYCIN	Powder for	Antineoplastic Agents, NEC	
63323019202	FLUDARABINE	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
63323019302	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323019305	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323019405	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323019410	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323019420	IDARUBICIN	IDARUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323019606	FLUDARABINE	FLUDARABINE PHOSPHATE	Powder for	Antineoplastic Agents, NEC	
63323027810	VINBLASTINE	VINBLASTINE SULFATE	Solution	Antineoplastic Agents, NEC	
63323076305	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
63323076316	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
63323076350	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
63323088305	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323088310	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
63323088330	DOXORUBICIN	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	

63459039008	TREANDA	Bendamustine Hydrochloride	Powder for	Antineoplastic	Agents, NEC
63459039120	TREANDA	Bendamustine Hydrochloride	Powder for	Antineoplastic	Agents, NEC
63459060010	TRISENOX	ARSENIC TRIOXIDE	Solution	Antineoplastic	Agents, NEC
63629126201	AROMASIN	EXEMESTANE	Tablet	Antineoplastic	Agents, NEC
63739026910	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
63739026915	TAMOXIFEN	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC
63857032322	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
63857033218	BLEOMYCIN	BLEOMYCIN SULFATE	Powder for	Antineoplastic	Agents, NEC
64067021601	UVADEX	METHOXSALEN	Solution	Antineoplastic	Agents, NEC
64365050201	TARGRETIN	BEXAROTENE	Capsule	Antineoplastic	Agents, NEC
64365050301	ONTAK	DENILEUKIN DIFTITOX	Solution	Antineoplastic	Agents, NEC
64370021001	AMERINET	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64370025001	AMERINET	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64370053201	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64370053202	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64370308601	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64370308602	NAVELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic	Agents, NEC
64406010303	ZEVALIN Y-90	Ibritumomab Tiuxetan	Solution	Antineoplastic	Agents, NEC
64406010404	ZEVALIN IN-111	Ibritumomab Tiuxetan	Solution	Antineoplastic	Agents, NEC
64523010001	OAKLIDE	LEUPROLIDE ACETATE	Solution	Antineoplastic	Agents, NEC
64523010002	OAKLIDE	LEUPROLIDE ACETATE	Kit	Antineoplastic	Agents, NEC
66105083201	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic	Agents, NEC

66105083203	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
66105083206	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
66105083209	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
66105083210	NOLVADEX	TAMOXIFEN CITRATE	Tablet	Antineoplastic Agents, NEC	
66116021230	CASODEX	BICALUTAMIDE	Tablet	Antineoplastic Agents, NEC	
66733094823	ERBITUX	Cetuximab	Solution	Antineoplastic Agents, NEC	
66733095823	ERBITUX	Cetuximab	Solution	Antineoplastic Agents, NEC	
66758004301	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
66758004302	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
66758004303	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic Agents, NEC	
66758004401	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
66758004403	FLUOROURACIL	FLUOROURACIL	Solution	Antineoplastic Agents, NEC	
66758004501	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
66758004502	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC	
66758004601	FLUDARABINE	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC	
66758004701	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
66758004702	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
66758004703	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic Agents, NEC	
66758004801	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
66758004802	IRINOTECAN	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC	
66758005301	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic Agents, NEC	
66758005302	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic Agents, NEC	

67211010201	VIDAZA	Azacitidine	Powder for	Antineoplastic NEC	Agents,
67253019103	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
67253019110	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
67286005308	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
67286005408	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
67386041151	ELSPAR	ASPARAGINASE	Powder for	Antineoplastic NEC	Agents,
67386081155	COSMEGEN	DACTINOMYCIN	Powder for	Antineoplastic NEC	Agents,
67386091151	MUSTARGEN	MECHLORETHAMINE	Powder for	Antineoplastic NEC	Agents,
67800010131	BEXXAR	Tositumomab	Solution	Antineoplastic NEC	Agents,
67800010132	BEXXAR	Tositumomab	Solution	Antineoplastic NEC	Agents,
67800011110	BEXXAR	Iodine I 131 Tositumomab	Solution	Antineoplastic NEC	Agents,
67800012110	BEXXAR	Iodine I 131 Tositumomab	Solution	Antineoplastic NEC	Agents,
67817006112	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
67817006312	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
67817006612	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
67817006712	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
67979000101	VALSTAR	VALRUBICIN	Solution	Antineoplastic NEC	Agents,
67979000102	VALSTAR	VALRUBICIN	Solution	Antineoplastic NEC	Agents,
68084032521	MERCAPTOPURI	MERCAPTOPURINE	Tablet	Antineoplastic NEC	Agents,
68084037421	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
68152010303	ZEVALIN Y-90	Ibritumomab Tiuxetan/Sodium	Solution	Antineoplastic NEC	Agents,
68152010404	ZEVALIN IN-111	Ibritumomab Tiuxetan/Sodium	Solution	Antineoplastic NEC	Agents,

68158014901	PLENAXIS	Abarelix/Sodium Chloride	Kit	Antineoplastic NEC	Agents,
68158014951	PLENAXIS	Abarelix/Sodium Chloride	Kit	Antineoplastic NEC	Agents,
68185014951	PLENAXIS	Abarelix/Sodium Chloride	Kit	Antineoplastic NEC	Agents,
68382022401	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
68382022405	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
68382022406	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
68382022410	BICALUTAMIDE	BICALUTAMIDE	Tablet	Antineoplastic NEC	Agents,
68817013450	ABRAXANE	Paclitaxel Protein-Bound	Powder for	Antineoplastic NEC	Agents,
57894015012	~~ZYTIGA~~	~~Abiraterone Acetate~~	~~Tablet~~	Antineoplastic	Agents, NE
50242008701	KADCYLA	Ado-Trastuzumab Emtansine	Powder Sol	foruAntineoplastic NEC	Agents,
50242008801	KADCYLA	Ado-Trastuzumab Emtansine	Powder Sol	foruAntineoplastic NEC	Agents,
00597013730	GILOTRIF	Afatinib Dimaleate	Tablet	Antineoplastic NEC	Agents,
00597013830	GILOTRIF	Afatinib Dimaleate	Tablet	Antineoplastic NEC	Agents,
00597014130	GILOTRIF	Afatinib Dimaleate	Tablet	Antineoplastic NEC	Agents,
65483011607	PROLEUKIN	ALDESLEUKIN	Powder Sol	foruAntineoplastic NEC	Agents,
58468035703	CAMPATH	ALEMTUZUMAB	Solution	Antineoplastic NEC	Agents,
62856000110	HEXALEN	ALTRETAMINE	Capsule	Antineoplastic NEC	Agents,
57902024901	ERWINAZE	Asparaginase Erwinia Chrysanthem	Powder Sol	foruAntineoplastic NEC	Agents,
57902024905	ERWINAZE	Asparaginase Erwinia Chrysanthem	Powder Sol	foruAntineoplastic NEC	Agents,
00069014501	INLYTA	Axitinib	Tablet	Antineoplastic NEC	Agents,
00069015111	INLYTA	Axitinib	Tablet	Antineoplastic NEC	Agents,
49281088003	THERACYS	Bacillus of Calmette and Guerinc Va	Powder Sus	forAntineoplastic NEC	Agents,

00069013501	BOSULIF	Bosutinib	Tablet	Antineoplastic NEC	Agents,
00069013601	BOSULIF	Bosutinib	Tablet	Antineoplastic NEC	Agents,
51144005001	ADCETRIS	Brentuximab Vedotin	Powder Sol	foruAntineoplastic NEC	Agents,
59148007090	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
59148007190	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
59148007191	BUSULFEX	BUSULFAN	Solution	Antineoplastic NEC	Agents,
76388071325	MYLERAN	BUSULFAN	Tablet	Antineoplastic NEC	Agents,
00024582411	JEVTANA	Cabazitaxel	Solution	Antineoplastic NEC	Agents,
42388001114	COMETRIQ	Cabozantinib Malate	Capsule	Antineoplastic NEC	Agents,
42388001214	COMETRIQ	Cabozantinib Malate	Capsule	Antineoplastic NEC	Agents,
42388001314	COMETRIQ	Cabozantinib Malate	Capsule	Antineoplastic NEC	Agents,
00004110175	XELODA	CAPECITABINE	Tablet	Antineoplastic NEC	Agents,
66758004704	CARBOPLATIN	CARBOPLATIN	Solution	Antineoplastic NEC	Agents,
76075010101	KYPROLIS	Carfilzomib	Powder Sol	foruAntineoplastic NEC	Agents,
23155026141	BICNU	CARMUSTINE	Powder Sol	foruAntineoplastic NEC	Agents,
62856017708	GLIADEL	CARMUSTINE	Implant	Antineoplastic NEC	Agents,
76388063550	LEUKERAN	CHLORAMBUCIL	Tablet	Antineoplastic NEC	Agents,
00069008101	CISPLATIN	CISPLATIN	Solution	Antineoplastic NEC	Agents,
00069008407	CISPLATIN	CISPLATIN	Solution	Antineoplastic NEC	Agents,
00069008618	CLADRIBINE	CLADRIBINE	Solution	Antineoplastic NEC	Agents,
00069020101	NOVAPLUS CLADR	CLADRIBINE	Solution	Antineoplastic NEC	Agents,
00069814020	XALKORI	Crizotinib	Capsule	Antineoplastic NEC	Agents,

00069814120	XALKORI	Crizotinib	Capsule	Antineoplastic NEC	Agents,
00069015201	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00069015202	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00069015301	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00069015302	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00069015401	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00069015501	CYTARABINE	CYTARABINE	Solution	Antineoplastic NEC	Agents,
00173084608	TAFINLAR	Dabrafenib Mesylate	Capsule	Antineoplastic NEC	Agents,
00173084708	TAFINLAR	Dabrafenib Mesylate	Capsule	Antineoplastic NEC	Agents,
55390033701	DACTINOMYCIN	DACTINOMYCIN	Powder Sol	foruAntineoplastic NEC	Agents,
00003085522	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
00003085722	SPRYCEL	Dasatinib	Tablet	Antineoplastic NEC	Agents,
10885000101	DAUNOXOME	DAUNORUBICIN CITRATE LIPOSOM	Solution	Antineoplastic NEC	Agents,
00703523391	NOVAPLUS DAUN	ODAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00703523393	NOVAPLUS DAUN	ODAUNORUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
55111055610	DECITABINE	Decitabine	Powder Sol	foruAntineoplastic NEC	Agents,
55566830102	FIRMAGON	Degarelix Acetate	Powder Sol	foruAntineoplastic NEC	Agents,
55566830301	FIRMAGON	Degarelix Acetate	Powder Sol	foruAntineoplastic NEC	Agents,
55566840102	FIRMAGON	Degarelix Acetate	Powder Sol	foruAntineoplastic NEC	Agents,
55566840301	FIRMAGON	Degarelix Acetate	Powder Sol	foruAntineoplastic NEC	Agents,
00075800301	TAXOTERE	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
00075800404	TAXOTERE	DOCETAXEL	Solution	Antineoplastic NEC	Agents,

00409020102	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
00409020110	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
00409020120	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
00955102001	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
00955102104	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729012049	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729012050	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729023163	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729023164	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729023165	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729026763	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729026764	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
16729026765	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
25021022201	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
25021022204	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
25021022207	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
47335028541	DOCEFREZ	DOCETAXEL	Powder Sol foru	Antineoplastic NEC	Agents,
47335028641	DOCEFREZ	DOCETAXEL	Powder Sol foru	Antineoplastic NEC	Agents,
60505603506	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
60505603706	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,
66758005001	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic NEC	Agents,

66758005002	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic Agents, NEC
66758005003	DOCETAXEL	DOCETAXEL	Solution	Antineoplastic Agents, NEC
00069017001	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Powder foruSol	Antineoplastic Agents, NEC
00069017101	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Powder foruSol	Antineoplastic Agents, NEC
00069303020	DOXORUBICIN HC	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069303120	DOXORUBICIN HC	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069303220	DOXORUBICIN HC	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069303320	DOXORUBICIN HC	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069303420	DOXORUBICIN HC	DOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069403001	NOVAPLUS DOXO	RDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069403101	NOVAPLUS DOXO	RDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069403201	NOVAPLUS DOXO	RDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069403301	NOVAPLUS DOXO	RDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00069403401	NOVAPLUS DOXO	RDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
53150031410	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
53150031501	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
53150031701	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
53150032010	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
62756082640	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
62756082740	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
47335004940	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic Agents, NEC
47335005040	DOXORUBICIN HY	DDOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic Agents, NEC

47335008250	LIPODOX	DOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic NEC	Agents,
47335008350	LIPODOX 50	DOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic NEC	Agents,
59676096001	DOXIL	DOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic NEC	Agents,
59676096002	DOXIL	DOXORUBICIN HYDROCHLORIDE LI	PSolution	Antineoplastic NEC	Agents,
00469012599	XTANDI	Enzalutamide	Capsule, Liquid	Antineoplastic NEC	Agents,
53150024701	EPIRUBICIN HYDR	OEPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
53150025001	EPIRUBICIN HYDR	OEPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
66758004201	EPIRUBICIN HYDR	OEPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
66758004202	EPIRUBICIN HYDR	OEPIRUBICIN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
62856038901	HALAVEN	Eribulin Mesylate	Solution	Antineoplastic NEC	Agents,
00703565691	NOVAPLUS TOPO	SETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00703565791	NOVAPLUS TOPO	SETOPOSIDE	Solution	Antineoplastic NEC	Agents,
16729011431	ETOPOSIDE	ETOPOSIDE	Solution	Antineoplastic NEC	Agents,
00078059451	AFINITOR	Everolimus	Tablet	Antineoplastic NEC	Agents,
00078059461	AFINITOR	Everolimus	Tablet	Antineoplastic NEC	Agents,
00078062051	AFINITOR	Everolimus	Tablet	Antineoplastic NEC	Agents,
00078062061	AFINITOR	Everolimus	Tablet	Antineoplastic NEC	Agents,
00078062651	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic NEC	Agents,
00078062661	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic NEC	Agents,
00078062751	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic NEC	Agents,
00078062761	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic NEC	Agents,

00078062851	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic Agents, NEC
00078062861	AFINITOR DISPERZ	Everolimus	Tablet Susp	foreAntineoplastic Agents, NEC
00069932122	FLUDARABINE PH	OFLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC
00703485291	NOVAPLUS FLUDA	FLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC
67457023802	FLUDARABINE PH	OFLUDARABINE PHOSPHATE	Solution	Antineoplastic Agents, NEC
00069385710	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00069385810	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00069385910	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00409018101	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00409018201	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00409018301	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00409018501	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00409018601	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00409018701	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00591356279	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00591356355	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00703577501	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00703577801	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00781328275	GEMCITABINE HY	DGEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00781328379	GEMCITABINE HY	DGEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
16729009203	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
16729011711	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC

16729011838	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
23155021331	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
23155021431	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
25021020810	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
25021020950	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
47335015340	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
47335015440	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
55111068607	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
55111068725	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
55390039110	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
55390039150	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
63323010210	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
63323010213	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
63323012550	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
63323012553	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
63323012600	GEMCITABINE	GEMCITABINE HYDROCHLORIDE	Powder Sol	foruAntineoplastic Agents, NEC
00003083050	HYDREA	HYDROXYUREA	Capsule	Antineoplastic Agents, NEC
00003633517	DROXIA	HYDROXYUREA	Capsule	Antineoplastic Agents, NEC
00003633617	DROXIA	HYDROXYUREA	Capsule	Antineoplastic Agents, NEC
00003633717	DROXIA	HYDROXYUREA	Capsule	Antineoplastic Agents, NEC
00555088202	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic Agents, NEC

42291032101	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
49884072401	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54569571500	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54868136700	HYDREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54868477300	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54868477301	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54868477302	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
54868477303	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
60429026501	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
68084028401	HYDROXYUREA	HYDROXYUREA	Capsule	Antineoplastic NEC	Agents,
00069449522	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic NEC	Agents,
00069449622	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic NEC	Agents,
63323017420	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic NEC	Agents,
63323017460	IFOSFAMIDE	IFOSFAMIDE	Solution	Antineoplastic NEC	Agents,
54868542703	GLEEVEC	IMATINIB MESYLATE	Tablet	Antineoplastic NEC	Agents,
00003232711	YERVOY	Ipilimumab	Solution	Antineoplastic NEC	Agents,
00003232822	YERVOY	Ipilimumab	Solution	Antineoplastic NEC	Agents,
00009111101	NOVAPLUS CAMP	TIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009111102	NOVAPLUS CAMP	TIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009752903	CAMPTOSAR	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009752904	CAMPTOSAR	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00009752905	CAMPTOSAR	IRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,

00143970101	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
00143970201	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
23155017931	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
23155017932	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021021402	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
25021021405	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
63323019352	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
63323019355	IRINOTECAN HYD	RIRINOTECAN HYDROCHLORIDE	Solution	Antineoplastic NEC	Agents,
58181303005	LOMUSTINE	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
58181303105	LOMUSTINE	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
58181303205	LOMUSTINE	LOMUSTINE	Capsule	Antineoplastic NEC	Agents,
00054460325	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00054460425	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00054860325	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00054860425	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00555060602	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00555060702	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00555060704	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
00904357161	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
49884028901	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
49884029001	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,

49884029004	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
49884029005	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
51079043401	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
51079043420	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
51079043501	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
51079043520	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
52959092830	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
54868162900	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
54868162901	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
54868162902	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
54868162903	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
57866482201	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
63739016510	MEGESTROL ACET	MEGESTROL ACETATE	Tablet	Antineoplastic NEC	Agents,
52609000105	ALKERAN	MELPHALAN	Tablet	Antineoplastic NEC	Agents,
52609300100	ALKERAN	Melphalan Hydrochloride	Powder Sol	foruAntineoplastic NEC	Agents,
67457019501	MELPHALAN HYD	RMelphalan Hydrochloride	Powder Sol	foruAntineoplastic NEC	Agents,
67457021501	NOVAPLUS MELP	HMelphalan Hydrochloride	Powder Sol	foruAntineoplastic NEC	Agents,
54868528202	MERCAPTOPURIN	MERCAPTOPURINE	Tablet	Antineoplastic NEC	Agents,
16729011638	MITOMYCIN	MITOMYCIN	Powder Sol	foruAntineoplastic NEC	Agents,
00078059251	TASIGNA	Nilotinib Hydrochloride	Capsule	Antineoplastic NEC	Agents,
00078059287	TASIGNA	Nilotinib Hydrochloride	Capsule	Antineoplastic NEC	Agents,
00173082101	ARZERRA	Ofatumumab	Solution	Antineoplastic NEC	Agents,

00173082133	ARZERRA	Ofatumumab	Solution	Antineoplastic NEC	Agents,
63459017714	SYNRIBO	Omacetaxine Mepesuccinate	Powder Sol	foruAntineoplastic NEC	Agents,
00069006701	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
00069007001	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
00069007401	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
00069101001	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
25021021120	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
25021021250	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
41616017640	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
47335017640	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
47335017840	OXALIPLATIN	OXALIPLATIN	Powder Sol	foruAntineoplastic NEC	Agents,
63323065010	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
63323065017	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
63323065020	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
63323065027	OXALIPLATIN	OXALIPLATIN	Solution	Antineoplastic NEC	Agents,
00069007601	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
00069007801	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
00069007901	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
25021021305	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
25021021317	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,
25021021350	PACLITAXEL	PACLITAXEL	Solution	Antineoplastic NEC	Agents,

54482030101	ONCASPAR	PEGASPARGASE	Solution	Antineoplastic NEC	Agents,
50242014501	PERJETA	Pertuzumab	Solution	Antineoplastic NEC	Agents,
59572050100	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050121	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050200	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050221	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050300	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050321	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050400	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
59572050421	POMALYST	Pomalidomide	Capsule	Antineoplastic NEC	Agents,
76189053430	ICLUSIG	Ponatinib Hydrochloride	Tablet	Antineoplastic NEC	Agents,
76189053560	ICLUSIG	Ponatinib Hydrochloride	Tablet	Antineoplastic NEC	Agents,
76128015575	PHOTOFRIN	PORFIMER SODIUM	Powder for Sol u	Antineoplastic NEC	Agents,
50419020801	XOFIGO	Radium Ra 223 Dichloride	Solution	Antineoplastic NEC	Agents,
50419017103	STIVARGA	Regorafenib	Tablet	Antineoplastic NEC	Agents,
46026098301	ISTODAX	Romidepsin	Powder for Sol u	Antineoplastic NEC	Agents,
59572098301	ISTODAX	Romidepsin	Powder for Sol u	Antineoplastic NEC	Agents,
00085136603	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic NEC	Agents,
00085136604	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic NEC	Agents,
00085141702	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic NEC	Agents,
00085142503	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic NEC	Agents,
00085142504	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic NEC	Agents,

00085143003	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085143004	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085151903	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085151904	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085300403	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00085300404	TEMODAR	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093759941	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093759957	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093760041	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093760057	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093760141	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093760157	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093760257	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093763841	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093763857	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093763941	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00093763957	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00781269144	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00781269175	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00781269244	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00781269275	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	
00781269344	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC	

00781269375	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
00781269444	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
00781269475	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
00781269544	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
00781269575	TEMOZOLOMIDE	TEMOZOLOMIDE	Capsule	Antineoplastic Agents, NEC
44567050701	TENIPOSIDE	TENIPOSIDE	Solution	Antineoplastic Agents, NEC
76388088025	TABLOID	THIOGUANINE	Tablet	Antineoplastic Agents, NEC
00069007501	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
00409030201	TOPOTECAN	TOPOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00703471401	TOPOTECAN	TOPOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
00703471471	TOPOTECAN	TOPOTECAN HYDROCHLORIDE	Solution	Antineoplastic Agents, NEC
16729015131	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
25021020606	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
25021020661	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
25021082406	NOVAPLUS TOPO	TTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
55390037010	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
63323076210	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
63323076217	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
63323076294	PREMIERPRO RX T	TOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
66435041005	TOPOTECAN HYD	RTOPOTECAN HYDROCHLORIDE	Powder Sol foru	Antineoplastic Agents, NEC
00173084813	MEKINIST	Trametinib Dimethyl Sulfoxide	Tablet	Antineoplastic Agents, NEC

00173084913	MEKINIST	Trametinib Dimethyl Sulfoxide	Tablet	Antineoplastic Agents, NEC
10370026801	TRETINOIN	TRETINOIN	Capsule, Liquid	Antineoplastic Agents, NEC
68084007511	TRETINOIN	TRETINOIN	Capsule, Liquid	Antineoplastic Agents, NEC
68084007521	TRETINOIN	TRETINOIN	Capsule, Liquid	Antineoplastic Agents, NEC
00310781030	VANDETANIB	Vandetanib	Tablet	Antineoplastic Agents, NEC
00310782030	CAPRELSA	Vandetanib	Tablet	Antineoplastic Agents, NEC
00310783030	VANDETANIB	Vandetanib	Tablet	Antineoplastic Agents, NEC
00310784030	CAPRELSA	Vandetanib	Tablet	Antineoplastic Agents, NEC
50242009001	ZELBORAF	Vemurafenib	Tablet	Antineoplastic Agents, NEC
20536032201	MARQIBO	vinCRIStine sulfate liposome	Suspension	Antineoplastic Agents, NEC
00069009901	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
00069010303	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
00069020510	NOVAPLUS VINOR	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
00069020550	NOVAPLUS VINOR	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
25021020401	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
25021020405	VINORELBINE	VINORELBINE TARTRATE	Solution	Antineoplastic Agents, NEC
50242014001	ERIVEDGE	Vismodegib	Capsule	Antineoplastic Agents, NEC
00024584001	ZALTRAP	Ziv-Aflibercept	Solution	Antineoplastic Agents, NEC
00024584101	ZALTRAP	Ziv-Aflibercept	Solution	Antineoplastic Agents, NEC
00002448354	VERZENIO	ABEMACICLIB	Tablet	Antineoplastic Agents, NEC
00002481554	VERZENIO	ABEMACICLIB	Tablet	Antineoplastic Agents, NEC
00002533754	VERZENIO	ABEMACICLIB	Tablet	Antineoplastic Agents, NEC
00002621654	VERZENIO	ABEMACICLIB	Tablet	Antineoplastic Agents, NEC
00008010001	BESPONSA	INOTUZUMAB OZOGAMICIN	Powder for Solu	Antineoplastic Agents, NEC

00310051260	CALQUENCE	ACALABRUTINIB	Capsule	Antineoplastic Agents, NEC
00310051228	CALQUENCE	ACALABRUTINIB	Capsule	Antineoplastic Agents, NEC
50242010801	RITUXAN HYCELA	RITUXIMAB AND HYALURONIDASE	Solution	Antineoplastic Agents, NEC
50242010901	RITUXAN HYCELA	RITUXIMAB AND HYALURONIDASE	Solution	Antineoplastic Agents, NEC
50242010886	RITUXAN HYCELA	RITUXIMAB AND HYALURONIDASE	Solution	Antineoplastic Agents, NEC
50419038501	ALIQOPA	COPANLISIB DI-HCL	Powder for Solu	Antineoplastic Agents, NEC
59572070530	IDHIFA	ENASIDENIB MESYLATE	Tablet	Antineoplastic Agents, NEC
59572071030	IDHIFA	ENASIDENIB MESYLATE	Tablet	Antineoplastic Agents, NEC
59676060012	ERLEADA	APALUTAMIDE	Tablet	Antineoplastic Agents, NEC
59676060099	ERLEADA	APALUTAMIDE	Tablet	Antineoplastic Agents, NEC
68727074501	VYXEOS	DAUNORUBICIN AND CYTARABINE	Powder for Sus	Antineoplastic Agents, NEC
68727074502	VYXEOS	DAUNORUBICIN AND CYTARABINE	Powder for Sus	Antineoplastic Agents, NEC
68727074505	VYXEOS	DAUNORUBICIN AND CYTARABINE	Powder for Sus	Antineoplastic Agents, NEC
70437024026	NERLYNX	NERATINIB MALEATE	Tablet	Antineoplastic Agents, NEC
70437024018	NERLYNX	NERATINIB MALEATE	Tablet	Antineoplastic Agents, NEC
71287011901	YESCARTA	AXICABTAGENE CILOLEUCEL	Suspension	Antineoplastic Agents, NEC